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APE1/Ref-1 (hereafter, APE1), a DNA repair enzyme and a transcriptional coactivator, is a vital protein in
mammals. Its role in controlling cell growth and the molecular mechanisms that fine-tune its different cellular
functions are still not known. By an unbiased proteomic approach, we have identified and characterized several
novel APE1 partners which, unexpectedly, include a number of proteins involved in ribosome biogenesis and
RNA processing. In particular, a novel interaction between nucleophosmin (NPM1) and APE1 was character-
ized. We observed that the 33 N-terminal residues of APE1 are required for stable interaction with the NPM1
oligomerization domain. As a consequence of the interaction with NPM1 and RNA, APE1 is localized within
the nucleolus and this localization depends on cell cycle and active rRNA transcription. NPM1 stimulates
APE1 endonuclease activity on abasic double-stranded DNA (dsDNA) but decreases APE1 endonuclease
activity on abasic single-stranded RNA (ssRNA) by masking the N-terminal region of APE1 required for stable
RNA binding. In APE1-knocked-down cells, pre-rRNA synthesis and rRNA processing were not affected but
inability to remove 8-hydroxyguanine-containing rRNA upon oxidative stress, impaired translation, lower
intracellular protein content, and decreased cell growth rate were found. Our data demonstrate that APE1
affects cell growth by directly acting on RNA quality control mechanisms, thus affecting gene expression
through posttranscriptional mechanisms.
APE1/Ref-1 (also called HAP1 or APEX, and here referred
to as APE1), the mammalian ortholog of Escherichia coli Xth
(exonuclease III), is a vital protein (20) that acts as a master
regulator of cellular response to oxidative stress conditions and
contributes to the maintenance of genome stability (55, 56).
APE1 is involved in both the base excision repair (BER) path-
ways of DNA lesions, acting as the major apurinic/apyrimidinic
(AP) endonuclease, and in transcriptional regulation of gene
expression as a redox coactivator of different transcription
factors, such as early growth response protein 1 (Egr-1), NF-
B, and p53 (55, 56). These two biological activities are located
in two functionally distinct protein domains. In fact, the
N-terminal region, containing the nuclear localization signal
(NLS) sequence, is principally devoted to redox activity
through Cys65, while the C-terminal one exerts enzymatic ac-
tivity on the abasic sites of DNA (56, 63). The protein C
terminus is highly conserved during phylogenesis, while the N
terminus is not. Except in mammals, which always show a high
sequence conservation (more than 90%), and Danio, Drosoph-
ila, Xenopus, and Dictyostelium (presenting a sequence identity
of less than 40%), the N-terminal region is mostly absent in
other organisms. A third APE1 function, which is regulated by
Lys6/Lys7 acetylation (7), is indirect binding to the negative
calcium response elements (nCaRE) of some promoters (i.e.,
PTH and APE1 promoters), thus acting as a transcriptional
repressor (12, 30).
In different mammalian cell types, the APE1 subcellular
distribution is mainly nuclear and is critical for controlling
cellular proliferative rate (20, 25, 28). However, cytoplasmic,
mitochondrial, and endoplasmic reticulum localization has also
been reported (11, 22, 33, 50, 54). Interestingly, cytoplasmic
expression of APE1 has been correlated with aggressiveness of
different tumors (55, 56), although its role in tumorigenic pro-
cesses is completely unknown. To date, no subnuclear distri-
bution of APE1 has been reported. APE1 is an abundant
protein (about 104 to 105 copies/cell) within eukaryotic cells
and has a relatively long half-life (about 8 h). Thus, fine-tuning
of the multiple APE1 functions may reside on its posttransla-
tional modifications and on the modulation of its interactome
under different conditions. While some posttranslational mod-
ifications have a functional role (i.e., Lys6/Lys7 acetylation) (7,
17), little information is available on APE1 protein interacting
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partners, except for those that are involved in BER function
(38).
Interestingly, proteolysis at residue Lys31 has recently been
related to an enhanced immune cell death mediated by gran-
zymes A and K (16, 23). This proteolytic event reduces APE1
accumulation within nuclei (16, 29) and its interaction with
XRCC1 (60) and alters APE1 functions (16, 23). Recently,
proteolysis occurring at Asn33 (giving rise to a protein form
called N33APE1) has also been described (11), suggesting
that removal of the NLS may constitute a general mechanism
for redirecting APE1 toward noncanonical subcellular com-
partments, such as mitochondria (11, 33, 54). Unfortunately,
neither has the specific protease responsible for this cleavage
been identified in nonimmune cells, nor has the mitochondrial
localization signal been mapped yet. Mitochondrial localiza-
tion of APE1 could be associated with a potential role in
mtDNA repair of oxidized bases (11, 33, 54). However, since it
is not clear whether N33APE1 maintains its DNA repair
activity in vivo (16) or acquires an aspecific endonuclease
activity for double-stranded DNA (dsDNA) (66), at present
it is not possible to drive any definitive conclusion. More-
over, as the truncated N33APE1 form is associated with an
apoptotic phenotype (23), it cannot be excluded that its
generation may causatively be involved in the cytotoxic ef-
fect, driving proapoptotic triggering directly within mito-
chondria.
The first 42 amino acids of APE1 are highly unordered in the
protein crystallographic structure (3, 35), while the remainder
of the protein has a globular fold (21). It is therefore presum-
able that the protein’s N terminus is used for interacting with
other partners, thus modulating the different APE1 functions.
Interestingly, a similar bipartite arrangement for Rrp1, the
Drosophila homologue of mammalian APE1, has been de-
scribed, pointing out a functional role of the unstructured
N-terminal domain in modulating protein-protein interactions
(42, 52).
By using an unbiased proteomic approach, in this work we
have identified and characterized a novel APE1 complex. We
found that APE1 N terminus is essential for binding to a
number of proteins involved in ribosome biogenesis and RNA
processing. Among the interacting partners, we focused on the
nucleophosmin (NPM1)-APE1 interaction. NPM1 is an abun-
dant protein which specifically resides within the granular re-
gion of the nucleolus and has been implicated in a variety of
cellular processes, including centrosome duplication, mainte-
nance of the genome’s integrity, and ribosome biogenesis (19).
NPM1 has a chaperone activity regulated by phosphorylation
(51) and an endoribonuclease activity at a specific site of the
spacer region between the 5.8S and the 28S rRNAs (43). Here,
we demonstrate that the NPM1-APE1 interaction is required
for APE1 subnuclear localization and for modulating the
cleansing process of rRNA. Our data demonstrate that APE1
affects cell growth by directly acting on RNA quality control
mechanisms, thus possibly affecting gene expression through
posttranscriptional mechanisms.
MATERIALS AND METHODS
Inducible siRNA of APE1 and generation of APE1-knock-in cell lines. The
following oligonucleotides were used for the short hairpin RNA (shRNA) of
APE1: sense, 5-GATCCCCCCTGCCACACTCAAGATCTGCTTCAAGAGA
GCAGATCTTGAGTGTGGCAGGTTTTTGGAAA-3; and antisense, 5-AG
CTTTTCCAAAAACCTGCCACACTCAAGATCTGCTCTCTTGAAGCAGA
TCTTGAGTGTGGCAGGGGG-3. These sequences were drawn following the
empirical rules of Mittal (34) and were designed to recognize and bind to a
21-base sequence (underlined) placed 175 nucleotides after the AUG initiation
codon of the APE1 gene. As a control, we used the following scrambled
oligonucleotide sequences: sense, 5-GATCCCCAGTCTAACTCGCCACCC
CGTATTCAAGAGATACGGGGTGGCGAGTTAGACTTTTTTGGAAA-
3; antisense, 5-AGCTTTTCCAAAAAAGTCTAACTCGCCACCCCGTAT
CTCTTGAATACGGGGTGGCGAGTTAGACTGGG-3. These sequences
were checked with BLAST (http://www.ncbi.nlm.nih.gov/blast/) for their inability
to pair with any human cDNA sequence. The sequences were cloned into BglII
and HindIII restriction sites of pTER vector (57), which presents a tetracycline
(doxycycline)-responsive promoter to form the so-called pTER/APE1 vector and
pTER/Scr, respectively. In the first step, HeLa cells were transfected with
pcDNA6/TR to generate stable Tet repressor-expressing cell clones that were
selected for the acquired resistance by incubation with 5 g/ml blasticidin (In-
vitrogen, Milan, Italy) for 14 days. Individual clones were isolated by using cell
cloning cylinders (Sigma, Milan, Italy), transferred, and grown stepwise into
24-well, 12-well, and 6-well plates for expansion to 107 cells. Clone TR5 ex-
pressed the Tet repressor at the highest levels and was therefore selected for
transfection with pTER/APE1 vector previously linearized with Bst1107I (Fer-
mentas, St. Leon Rot, United Kingdom) and subjected to selection with Zeocin
(200 g/ml) (Invitrogen) for 14 to 21 days. Thirty single clones were isolated by
using cell cloning cylinders, transferred, and grown stepwise for expansion to 107
cells. As a control, we used cell clones transfected with the empty pTER vector
or with pTER/Scr vector. For inducible siRNA experiments, doxycycline (Sigma)
was added to the cell culture medium at the final concentration of 1 g/ml and
cells were grown for 10 days. Total cellular extracts were analyzed for APE1
expression by immunoblotting. The HeLa control cell clone was identified as
siScr, while the APE1-knocked-down cell clone was identified as siAPE1 (58).
For generation of APE1 knock-in cell lines, an APE1 expression vector was
generated by cloning an EcoRI-BamHI fragment from pFLAG-CMV-5.1/APE1
(Sigma) into p3XFLAG-CMV-14 vector (Sigma). To avoid the degradation of
the ectopic APE1 mRNA by the specific siRNA sequence described above, two
nucleotides of the APE1-cDNA coding sequence were mutated with site-directed
mutagenesis kits (Stratagene), leaving the APE1 amino acid sequence unaf-
fected: siRNA, 5-CCTGCCACACTCAAGATCTGC-3; and APE1, 5-CCTG
CAACGCTCAAGATCTGC-3. The N33APE1 deletion mutant was gener-
ated by PCR and subcloning from the full-length cDNA sequence. All of the
mutants were confirmed by DNA sequencing. Then, the APE1 siRNA clone was
transfected with p3XFLAG-CMV/APE1, the wild-type (WT) APE1, and a de-
letion mutant (N33APE1), previously digested with ScaI (Fermentas); 48 h
after transfection, the cells were subjected to selection with Geneticin (Invitro-
gen) for 14 days and selected for the acquired resistance. Individual clones were
isolated by using cell cloning cylinders, transferred, and grown for expansion to
107 cells in the presence of selective antibiotics. As control, the siRNA control
clone was transfected with the p3XFLAG-CMV-14 empty vector. After 10 days
of doxycycline treatment at the final concentration of 1 g/ml, total or nuclear
and cytoplasmic cellular extracts were analyzed for APE1 expression by immu-
noblotting, thus revealing the silencing of the endogenus APE1 and the expres-
sion of the ectopic flagged WT and mutant forms of the protein. All biologic data
were reproduced in at least two different cell clones for each model.
Cell culture and transient transfection experiments. HeLa cells were grown in
Dulbecco’s modified Eagle’s medium (Invitrogen) supplemented with 10% fetal
bovine serum (Euroclone, Milan, Italy), 100 U/ml penicillin, and 10 g/ml strep-
tomycin sulfate. One day before transfection, cells were seeded in 10-cm plates
at a density of 1.8  106 cells/plate. Cells were then transiently transfected with
12 g of either pFLAG5.1 (empty vector) or pFLAG5.1-APE1 plasmid per dish,
using Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer’s
instructions. Cells were harvested 48 h after transfection.
Preparation of cell extracts and anti-Flag coimmunoprecipitation. For prep-
aration of total cell lysates and coimmunoprecipitation, cells were harvested by
trypsinization and centrifuged at 250  g for 5 min at 4°C. Supernatant was
removed, and the pellet was washed once with ice-cold phosphate-buffered saline
(PBS) and then centrifuged again as described before. Cell pellet was resus-
pended in lysis buffer containing 50 mM Tris HCl (pH 7.4), 150 mM NaCl, 1 mM
EDTA, and 1% [wt/vol] Triton X-100 supplemented with 1 protease inhibitor
cocktail (Sigma), 0.5 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM NaF,
and 1 mM Na3VO4, at a cell density of 107 cells/ml and rotated for 30 min at 4°C.
After centrifugation at 12,000  g for 10 min at 4°C, the supernatant was
collected as total cell lysate. The protein concentration was determined using
Bio-Rad protein assay reagent (Bio-Rad, Hercules, CA). Samples were then
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coimmunoprecipitated for 3 h using anti-Flag M2 affinity gel (Sigma) following
the manufacturer’s instructions. Proteins were eluted by incubation with 0.15
mg/ml 3 Flag peptide in Tris-buffered saline (TBS) and subjected to Western
blot analysis.
Nuclear protein extracts were prepared as described earlier (67). Briefly, cells
were washed and scraped into cold PBS and then centrifuged at 2,000  g for 10
min at 4°C. Supernatant was removed, and the pellet was resuspended in buffer
A (10 mM Tris-HCl [pH 7.5], 1.5 mM MgCl2, and 10 mM KCl supplemented
with 1 protease inhibitor cocktail, 0.5 mM PMSF, 1 mM NaF and 1 mM
Na3VO4) at a cell density of 3  107 cells/ml and incubated on ice for 10 min.
The nuclei were collected by centrifugation at 2,000  g for 10 min at 4°C and
then resuspended in buffer B (20 mM Tris-HCl [pH 7.5], 0.42 M KCl, 1.5 mM
MgCl2, 20% [vol/vol] glycerol supplemented with 1 protease inhibitor cocktail,
0.5 mM PMSF, 1 mM NaF, and 1 mM Na3VO4) and rotated for 30 min at 4°C.
The suspension was centrifuged at 15,000  g for 30 min at 4°C and dialyzed
against three changes of buffer C (25 mM Tris-HCl [pH 7.5], 0.2 mM EDTA, 0.1
M KCl, 20% [vol/vol] glycerol freshly supplemented with 1 protease inhibitor
cocktail, 0.5 mM PMSF, 1 mM NaF, and 1 mM Na3VO4) for 4 h, at 4°C. The
dialyzed sample was collected as nuclear protein extract and used for coimmu-
noprecipitation experiments.
2-DE differential proteomic analysis, evaluation of differentially represented
spots, and mass spectrometry analysis. Ten micrograms of immunoprecipitated
material from different samples was loaded onto 13-cm, pH 3 to 10 L IPG strips
(GE Healthcare, Milan, Italy). Isoelectric focusing was conducted using an
IPGPhor II system (GE Healthcare) according to the manufacturer’s instructions.
Focused strips were equilibrated with a mixture of 6 M urea, 26 mM dithiothre-
itol (DTT), 4% (wt/vol) sodium dodecyl sulfate (SDS), 30% (vol/vol) glycerol in
0.1 M Tris-HCl (pH 6.8) for 15 min, followed by 6 M urea, 0.38 M iodoacet-
amide, 4% (wt/vol) SDS, 30% (vol/vol) glycerol, and a dash of bromophenol blue
in 0.1 M Tris-HCl (pH 6.8) for 10 min. The equilibrated strips were applied
directly to 10% (wt/vol) SDS–polyacrylamide gels and separated at 130 V. Gels
were fixed and stained with ammoniacal silver (47). Gels were scanned with an
Image Scanner II apparatus and analyzed by the ImageMaster 2D Platinum
software (GE Healthcare), which allowed estimation of relative differences in
spot intensities for each represented protein.
Each sample was analyzed in triplicate, and then a comparative analysis was
carried out as previously reported (59). Differential spots from two-dimensional
electrophoresis (2-DE) were excised from the gel, triturated, and washed with
water. Proteins were in-gel reduced, S alkylated, and digested with trypsin as
previously reported (59). Digest aliquots were removed and subjected to a
desalting/concentration step on ZipTip C18 column (Millipore Corp., Bedford,
MA) using acetonitrile as the eluent before matrix-assisted laser desorption
ionization–time of flight mass spectrometry analysis. Peptide mixtures were
loaded on the matrix-assisted laser desorption ionization target, using the dried-
droplet technique and -cyano-4-hydroxycinnamic acid as the matrix, and ana-
lyzed by using a Voyager-DE PRO mass spectrometer (Applied Biosystems,
Framingham, MA). Spectra were elaborated using the DataExplorer 5.1 software
(Applied Biosystems) and manually inspected to get the peak lists. Internal mass
calibration was performed with peptides deriving from enzyme autoproteolysis.
PROWL and Matrix Science software packages were used to identify spots
unambiguously from all updated taxa from the NCBI nonredundant sequence
database (NCBInr 20080610, containing 6,573,034 protein sequences) by using a
mass tolerance value of 50 to 70 ppm, trypsin as the enzyme specificity, a
missed-cleavage maximum value of 2, and cysteine carbamidomethylation and
methionine oxidation as the fixed and variable modifications, respectively. Can-
didates with ProFound’s estimated Z scores of 1.8 and Mascot’s scores of 81
were further evaluated by the comparison with their calculated mass and pI using
the experimental values obtained from 2-DE.
Isolation of nucleoli. Nucleoli were isolated from HeLa cells by a variant of a
method described earlier (37) and recently adapted for this particular cell line by
Lamond and coworkers (http://lamondlab.com/f7nucleolarprotocol.htm). HeLa
cells were seeded onto 10- by 14-cm petri dishes and cultured at 37°C in a 5%
CO2 atmosphere until 90% of confluence, corresponding to 107 cells/dish. An
hour before nucleolar isolation, the medium was replaced with a fresh, pre-
warmed one. Cells were washed three times with PBS, harvested with trypsin-
EDTA solution (2 ml/dish), and collected. The pellet was washed three times
with cold PBS at 218  g at 4°C, and after the final wash, the pellet was
resuspended in 5 ml of buffer A (10 mM HEPES [pH 7.9], 10 mM KCl, 1.5 mM
MgCl2, 0.5 mM DTT) and incubated on ice for an additional 5 min. Then, the
cell suspension was transferred to a precooled 7-ml Dounce tissue homogenizer,
homogenized 10 times while keeping the cells on ice, and centrifuged at 218 
g for 5 min at 4°C. The pellet obtained contains entire, but not highly pure,
nuclei. The pellet was resuspended with 3 ml of S1 solution (0.25 M sucrose, 10
mM MgCl2), layered over 3 ml of S2 solution (0.35 M sucrose, 0.5 mM MgCl2),
and centrifuged at 1,430  g for 5 min at 4°C. With this step, a cleaner nuclear
pellet was obtained, which was resuspended in 3 ml of S2 solution and sonicated
on ice for six 10-s bursts to disrupt the nuclear membrane. The sonicated sample
was overlaid to 3 ml of S3 solution (0.885 M sucrose, 0.5 mM MgCl2) and
centrifuged at 3,000  g for 10 min at 4°C. The pellet was resuspended with 0.5
ml of S2 solution and centrifuged at 1,430  g for 5 min at 4°C. The resulting
pellet contained highly purified nucleoli, which were resuspended in 0.5 ml of S2
solution and stored at 	80°C or lysed with radioimmunoprecipitation assay
(RIPA) buffer (50 mM Tris HCl [pH 8.0], 150 mM NaCl, 1% [wt/vol] NP-40,
0.5% [wt/vol] deoxycholate, 0.1% [wt/vol] SDS, protease inhibitor cocktail) to
obtain highly purified nucleolar protein extracts. The products of each step of the
protocol were checked by using a phase-contrast microscope.
Plasmids and expression of recombinant proteins. The construct pGex2T-
APE1, coding for the glutathione S-transferase (GST)-APE1 full-length protein,
was kindly provided by Sankar Mitra (University of Texas Medical Branch,
Galveston, TX). The construct pGex2T-N33APE1 deletion mutant, coding for
the truncated APE1 lacking the first 33 N-terminal residues, was generated by
subcloning from the previous one through PCR and confirmed by direct sequenc-
ing. The plasmids coding for GST-NPM1 full-length and GST-NPM1 deletion
mutant proteins were kindly provided by P. G. Pelicci (European Institute of
Oncology, Milan, Italy). For expression of His6-tagged NPM1, cDNA coding for
full-length NPM1 was cloned in the pET-15b-expressing plasmid (Invitrogen).
All proteins were expressed in E. coli BL21(DE3), induced with 1 mM isopropyl-

-D-thiogalactopyranoside (IPTG), and then purified using the GSTrap HP
column (GE Healthcare) in the case of GST-tagged proteins or the HisTrap HP
column (GE Healthcare) in the case of His6-NPM1. An AKTA Prime (GE
Healthcare) fast protein liquid chromatography system was used for all purifi-
cation steps. In some cases, purification to the homogeneity was obtained by a
further gel filtration step. The quality of purification was checked by silver-
stained SDS-polyacrylamide gel electrophoresis (PAGE) analysis. Extensive di-
alysis against PBS was performed to remove any trace of imidazole from the
HisTrap-purified proteins.
Accurate quantification of all recombinant proteins was performed by color-
imetric Bradford assays (Bio-Rad) and confirmed by SDS-PAGE and by Western
blotting analysis using anti-GST peroxidase-conjugated antibody (Sigma). GST-
APE1 and GST-N33APE1 proteins were further hydrolyzed with thrombin (0.5
thrombin units per mg of recombinant GST-fused protein) to remove the GST
tag. The protease was then removed from the sample using a benzamidine
HiTrap FF column (GE Healthcare); and then APE1 was purified on a GSTrap
HP column (GE Healthcare). This recombinant cleaved form of APE1 was
identified as rAPE1 to differentiate it from the Flag-tagged and GST-tagged
APE1 proteins.
GST pull-down assay. For the GST pull-down experiments, 0.1 nmol of either
full-length GST-NPM1 or each GST-NPM1 deletion mutant protein was added,
together with 0.1 nmol of APE1 protein, to 10 l of glutathione-Sepharose 4B
beads (GE Healthcare). Binding was performed in PBS supplemented with 5
mM DTT and 1 protease inhibitor cocktail for 2 h under rotation at 4°C. The
beads were washed three times with washing buffer (PBS supplemented with
0.8% [wt/vol] Triton X-100, 5 mM DTT, 1 protease inhibitor cocktail). Beads
were boiled in 1 Laemmli sample buffer containing 100 mM DTT for 5 min,
and the supernatant was loaded onto 10% (wt/vol) SDS-PAGE gels followed by
Western blotting. The presence of APE1 protein was detected using anti-APE1
monoclonal antibody, while the presence of NPM1 protein was revealed using
anti-GST peroxidase-conjugated antibody (Sigma).
Cell cycle synchronization and flow cytometry. HeLa cells were synchronized
at the G1/S boundary by two cycles of thymidine blockage. Briefly, cells were
seeded at 3  104 to 4  104 cells/cm2 in six-well trays. After 24 h, cells were
treated with 2 mM thymidine (Sigma) in complete medium for 19 h and then
released in complete medium for 9 h and subjected to a second block with 2 mM
thymidine for 16 h. After the double block, cells were released in complete
medium and harvested at different time points. Cells were trypsinized, washed in
PBS, fixed in cold 70% (vol/vol) ethanol, and stained for fluorescence-activated
cell sorter (FACS) analysis in PBS containing 50 g/ml propidium iodide, 0.1%
(wt/vol) Triton X-100, and 10 g/ml RNase A for 20 min on ice. Cells were then
analyzed by FACS analysis using an Ar laser (excitation, 488 nm) on a Becton-
Dickinson (Franklin Lakes, NJ) FACScan equipped with ModFitLT V3.0 soft-
ware program.
Apoptosis measurements. Apoptosis was assessed by staining of phosphatidyl-
serines exposed on cell membranes with fluorescein isothiocyanate-labeled
annexin V, according to the manufacturer’s instructions (Roche Diagnostic Italia,
Monza, Italy). Samples were analyzed by flow cytometry using a FACScan. In
addition, caspase 3/7 activation was measured by an immunofluorescent assay
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(Apo-ONE homogeneous caspase assay; Promega Corp., Madison, WI) accord-
ing to the manufacturer’s instructions.
Immunofluorescence confocal analysis. For experiments on APE1-Flag/NCL
or APE1/NPM1 colocalization, a sequential protocol of double immunofluores-
cence was used, based on labeled goat anti-mouse isotype-specific secondary
antibodies. The nucleoli were detected with an antinucleolin (anti-NCL) (immu-
noglobulin G2b [IgG2b]) or an anti-NPM1 (IgG1) antibody (NCL, clone ZN004;
NPM1, clone FC-61991 [Zymed Laboratories, Invitrogen]). Cells fixed in 4%
(wt/vol) paraformaldehyde for 20 min at room temperature were permeabilized
for 5 min with PBS–0.25% (wt/vol) Triton X-100 and incubated for 30 min with
5% normal goat serum in PBS–0.1% (wt/vol) Triton X-100 (blocking solution) to
block unspecific binding of the antibodies. Cells were then incubated with the
mouse monoclonal anti-FLAG (IgG1) (Sigma) or APE1 (IgG2b) antibody (39),
diluted 1:1000 or 1:30, respectively, in blocking solution, for 2.5 h. After washing,
cells were incubated for 90 min with secondary antibody: Alexa Fluor 488-
conjugated goat anti-mouse IgG1 or Alexa Fluor 546-conjugated goat anti-
mouse IgG2b (1:200) (Molecular Probes, Invitrogen). After washing, a second
blocking step for 30 min in the dark was performed, and then the cells were
incubated overnight at 4°C with the second primary antibody—5 g/ml mouse
anti-NCL (IgG2b) or mouse anti-NPM1 (IgG1) in blocking solution. After wash-
ing, cells were incubated for 90 min with secondary antibody Alexa Fluor 546-
conjugated goat anti-mouse IgG2b or Alexa Fluor 488-conjugated goat anti-
mouse IgG1 (1:200; Molecular Probes). The preparations were then washed with
PBS three times for 5 min each in the dark. Nuclei were then stained by 5 min
of incubation in 300 nM solution of 4,6-diamidino-2-phenylindole dihydrochlo-
ride (DAPI) (Sigma) in PBS. The preparations were then washed three times in
PBS for 5 min. The microscope slides were then mounted onto slides in Mowiol
4-88 supplemented with DABCO (1:5) as an anti-fade reagent. Coverslips were
visualized through a Leica TCS SP laser-scanning confocal microscope (Leica
Microsystems, Wetzlar, Germany) equipped with a 488-nm argon laser, a 543-nm
HeNe laser, and a 63 oil fluorescence objective.
Actinomycin D (ActD; Sigma) solution was prepared in dimethyl sulfoxide
(DMSO). Cells were treated with 1 g/ml of ActD or vehicle for 40, 80, and 180
min, as previously described (1).
RNase A treatments were performed with certified DNase-free chromato-
graphically purified RNase A (Sigma catalog no. R6513). This protocol was a
modification of the previously published protocol (32). Fixed cells were perme-
abilized with 0.25% (wt/vol) Triton X-100 for 6 min at room temperature,
washed with PBS, incubated with 0.1 mg/ml RNase A (Sigma catalog no. R6513)
in PBS for 30 min at 37°C, washed three times with PBS–0.1% (wt/vol) Triton
X-100 for 5 min, and then processed for immunofluorescence. All experiments
were also performed with RNase A (Sigma catalog no. R5125) after inactivation
of residual contaminants by boiling at 100°C for 15 min, always obtaining the
same results.
Western blot analysis and antibodies. The indicated amounts of cell extracts
were electrophoresed onto a 12% SDS-PAGE. Proteins were then transferred to
nitrocellulose membranes (Schleicher & Schuell, Keene, NH). Membranes were
saturated by incubation at 4°C overnight with 5% (wt/vol) nonfat dry milk in
PBS–0.1% (wt/vol) Tween 20 and then incubated with the polyclonal anti-APE1
antibody (39) for 3 h. In the case of anti-NPM1 and anti-NCL, the specific
antibodies from Zymed (Invitrogen) were used. After three washes with PBS–
0.1% (wt/vol) Tween 20, membranes were incubated with an antirabbit Ig cou-
pled to peroxidase (Sigma). After 60 min of incubation at room temperature, the
membranes were washed three times with PBS–0.1% Tween 20 and the blots
were developed using the ECL enhanced chemiluminescence procedure (GE
Healthcare). Normalization was performed with the polyclonal antiactin or anti-

-tubulin antibodies (Sigma). Blots were quantified by using a Gel Doc 2000
video densitometer (Bio-Rad).
Coimmunoprecipitation and rRNA qRT-PCR. HeLa cells were transiently
transfected with APE1-Flag-, N33-Flag-, or NPM1-Flag-expressing plasmids, as
described above. Forty-eight hours after transfection, the cells were harvested by
trypsinization and centrifuged at 250  g for 5 min, at 4°C. Supernatant was
removed, and the pellet was washed once with ice-cold PBS and centrifuged
again as described before. The cell pellet was resuspended in lysis buffer (50 mM
Tris HCl [pH 7.4], 150 mM NaCl, 1 mM EDTA, 1% Triton X-100 supplemented
with 1 protease inhibitor cocktail, 0.5 mM PMSF, 1 mM NaF, 1 mM Na3VO4,
and 0.5 U/ml RNaseOUT [Invitrogen]) at a cell density of 107 cells per ml and
then rotated for 30 min at 4°C. After centrifugation at 12,000  g for 10 min, at
4°C, the supernatant was collected as total cell lysate. A fraction of each input
lysate was analyzed to quantify the total starting RNA. Total RNA was extracted
and purified using Trizol reagent (Invitrogen) according to the manufacturer’s
instructions. The RNA concentration was obtained spectrophotometrically, and
RNA integrity was checked on agarose-formaldehyde gels. Different amounts of
lysates, corresponding to the same quantity of total starting RNA, were subjected
to coimmunoprecipitation for 1 h using anti-Flag M2 affinity gel (Sigma), fol-
lowing the manufacturer’s instructions. Elution was performed by incubation
with 0.15 mg/ml 3 Flag peptide in TBS supplemented with 0.5 U/ml RNaseOUT.
Immunoprecipitates were then subjected to Western blot analysis or RNA
extraction using Trizol reagent, according to the manufacturer’s instructions.
Immunoprecipitated RNA was furthermore analyzed by quantitative real-
time reverse transcription-PCR (qRT-PCR) to determine for the presence of
the specific rRNA molecules coeluted with APE1 and NPM1 proteins.
Levels of 47S, 28S, and 18S rRNA transcripts were determined by methods
similar to those previously described (2). Total RNA was reverse transcribed
using the iScript cDNA synthesis kit (Bio-Rad) according to the manufacturer’s
instructions. qRT-PCR was performed with iQ5 multicolor real-time PCR
detection system (Bio-Rad), according to the manufacturer’s protocol. The
following primers were used: 47S_for (5-CGCCGCGCTCTACCTTACCTA-
3) and 47S_rev (5-TAGGAGAGGAGCGAGCGACCA-3), which amplified
a region of 174 bp; 18S_for (5-CTGCCCTATCAACTTTCGATGGTAG-3)
and 18S_rev (5-CCGTTTCTCAGGCTCCCTCTC-3), which amplified a re-
gion of 100 bp; and 28S_for (5-TGTCGGCTCTTCCTATCATTGT-3) and
28S_rev (5-ACCCAGCTCACGTTCCCTATTA-3), which amplified a re-
gion of 81 bp.
cDNA was amplified in 96-well plates using primers for 18S, 28S, and 47S
rRNA in separate wells using the 2X iQ SYBR green supermix (Bio-Rad) (100
mM KCl, 40 mM Tris-HCl [pH 8.4], 0.4 mM each deoxynucleoside triphosphate
[dNTP], 50 U/ml iTaq DNA polymerase, 6 mM MgCl2, SYBR green I, 20 nM
fluorescein, and stabilizers) and 300 nM of the specific sense and antisense
primers in a final volume of 15 l for each well. Each sample analysis was
performed in triplicate. As negative control, a sample without template was used;
as control for genomic DNA contamination, a sample with non-retro-transcribed
mRNA was included instead of template cDNA. The cycling parameters were
denaturation at 95°C for 10 s and annealing/extension at 60°C for 30 s (repeated
40 times). In order to verify the specificity of the amplification, a melting-curve
analysis was performed, immediately after the amplification protocol.
A standard curve was generated by using a calibrating cDNA. This cDNA was
obtained from a retrotranscription of 1 g of total RNA from input samples,
which was serially diluted and analyzed for 47S, 18S, and 28S rRNA. We as-
sumed that rRNA represented 90% of the total RNA in a molar ratio between
28S and 18S rRNA of 2:1. By using the equation describing the plots of the log10
of the starting amount of 5 dilutions of the calibrator cDNA versus the corre-
sponding threshold cycle, the iQ5 optical system software calculated the amount
of the template for each sample.
Evaluation of oxidized RNA through immunofluorescence and quantification
of 8-OHG rRNA by immunoprecipitation, qRT-PCR, and Northwestern analy-
sis. For immunofluorescence analysis of 8-hydroxyguanine (8-OHG)-modified
RNA, HeLa cells were plated onto glass coverslips. The day after plating, the
cells were maintained for 1 h in serum-free medium and then treated for 1 h with
50 M H2O2 or vehicle. The cultures were fixed with 2% paraformaldehyde
supplemented with 1.7% sucrose in phosphate buffer for 30 min at room tem-
perature. After being permeabilized with 0.1% saponin in PBS, the cultures were
incubated in serum-free medium supplemented with 1 mg/ml DNase I (Sigma)
for 1 h at 37°C and then with 0.1 mg/ml of RNase A (Sigma) or vehicle for 1 h
at 37°C. The cells were washed three times for 5 min each with TBS supple-
mented with 0.1% Triton X-100 and blocked with 10% (vol/vol) normal goat
serum in PBS with 0.1% (vol/vol) saponin (blocking solution) for 1 h at room
temperature and then incubated with primary antibody (mouse 15A3 at 1:200 in
blocking solution; QED Bioscience, San Diego, CA) overnight at room temper-
ature. After rinsing, the coverslips were incubated with secondary antibody
solution (Alexa Fluor 488 goat anti-mouse IgG at 1:200 in blocking solution) for
90 min at room temperature. DNase I efficiency was controlled by nuclear
staining with DAPI (4,6-diamidino-2-phenylindole). The coverslips were then
rinsed and mounted onto glass slides in Mowiol 4-88 supplemented with
DABCO (1:5) as an antifade reagent and then visualized through a Leica TCS SP
laser-scanning confocal microscope.
For immunoprecipitation experiments on 8-OHG containing rRNA, cells sta-
bly transfected with either APE1 shRNA- or scramble shRNA-encoding plas-
mids, were harvested after 10 days of doxycycline induction. Total RNA was
isolated using Trizol reagent, according to the manufacturer’s instructions. The
RNA concentration was obtained spectrophotometrically, and RNA integrity
was checked on agarose-formaldehyde gels. Oxidized RNA was immunoprecipi-
tated as described before (46), with minor modifications. Briefly, 1.5 g of total
RNA was incubated with 2.5 g of anti-8-OHG antibody 15A3 (QED Bio-
science) in 200 l of PBS supplemented with 400 U/ml RNaseOUT at room
temperature for 1 h, and then 20 l of protein G-Sepharose (Sigma) was added
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and the samples were rocked for another 15 h at 4°C. The beads were spun down
by centrifugation at 8,000  g for 1 min at 4°C and washed three times by PBS
with 0.04% (vol/vol) NP-40 (Sigma) (NP-40/PBS). The oxidized RNA/antibody/
protein G complexes were resuspended into 200 l of NP-40/PBS supplemented
with 1% (wt/vol) SDS. RNA was isolated by adding 250 l of Trizol reagent. The
mixture was incubated for 15 min at 37°C with vortexing every 5 min, and then
samples were further processed following the manufacturer’s instructions. Im-
munoprecipitated RNAs and 1 g of total input RNAs were reverse transcribed
using the iScript cDNA synthesis kit (Bio-Rad) and then further analyzed by
qRT-PCR as described before.
Northwestern analysis to evaluate the amount of 8-OHG was performed as
previously reported (14), with modifications. As a control of the specificity of the
detection analysis, a standard curve was also prepared with in vitro-oxidized
RNA, as follows. Purified RNA (1.5 g) was oxidized with increasing concen-
trations of H2O2 and cytochrome c (ratio of 16:1) for 1 h at 37°C as previously
reported (45). RNA was denatured by addition of formamide (50%) and form-
aldehyde (2.2 M) and incubated for 15 min at 55°C. Samples were blotted onto
Hybond-N membrane (GE Healthcare) using a vacuum slot-blot apparatus
(GE Healthcare) following the manufacturer’s instructions. RNA was cross-
linked to the membrane through UV irradiation (150 mJ). After blocking with
5% (wt/vol) nonfat dry milk in PBS–0.1% (wt/vol) Tween 20 for 1 h, the mem-
brane was incubated with the anti-8-OHG primary antibody (QED Bioscience)
for 1 h, followed by incubation with peroxidase-conjugated antimouse secondary
antibody. The immunoreactive bands were detected using the ECL system.
AP site incision assays. The determination of AP endonuclease activity was
performed using an oligonucleotide cleavage assay as described previously (64).
Recombinant proteins were incubated with a 5-32P-end-labeled 26-mer oligo-
nucleotide containing a single tetrahydrofuranyl (here called dsFDNA) artificial
AP site at position 14, which is cleaved to a 14-mer in the presence of AP
endonuclease activity. For the endonuclease assay with AP single-stranded RNA,
we used the recently published (5) sequence 34FRNA (here designated as
ssFRNA). Reactions from reaction mixtures (10 l) containing the proteins
of interest, 2.5 pmol of the 5-32P end-labeled oligonucleotide dsFDNA or
ssFRNA, 50 mM HEPES, 50 mM KCl, 10 mM MgCl2, 1 g/l bovine serum
albumin, and 0.05% (wt/vol) Triton X-100 (pH 7.5) were allowed to proceed for
15 min in a 37°C water bath. Reactions were halted by adding 10 l of 96%
(vol/vol) formamide and 10 mM EDTA, with xylene cyanol and bromophenol
blue as dyes. AP assay products (5 l) were separated on a 20% polyacrylamide
gel containing 7 M urea. Gels were wrapped in Saran wrap and exposed to film
for autoradiography.
APE1 and NPM1 RNA binding assays. APE1 and NPM1 RNA complex
formation was assessed as described previously (62), with assay mixtures incu-
bated on ice for 10 min and separated on a native 8% (wt/vol) polyacrylamide gel
at 120 V for 2 h. Each reaction mixture contained 2.5 pmol of RNA-labeled
substrate and the indicated amount of proteins in a final volume of 10 l.
Luciferase reporter assay. Luciferase mRNA was in vitro transcribed using T7
luciferase control DNA (Promega) as template and the T7 RiboMAX Express
large-scale RNA production system (Promega), following the manufacturer’s
instructions. Cells expressing or not expressing endogenous APE1 were seeded
on six-well plates 1 day before transfection and after 5 or 10 days of induction
with doxycycline, at a cell density of 400,000 cells/well. Then, cells were trans-
fected with 4 g of in vitro-transcribed luciferase mRNA and 100 ng of 
-ga-
lactosidase (
-Gal)-encoding vector for normalization of transfection efficiency
(17) per well and using Lipofectamine 2000 reagent (Invitrogen), following the
manufacturer’s instructions. Cells were harvested 20 h after tranfection and lysed
using 1 Promega cell culture lysis reagent. The luciferase assay was performed
using the Promega luciferase assay system and a TD-20/20 luminometer (Turner
BioSystems). Samples were normalized for total protein content by using Bio-
Rad protein assay reagent and transfection efficiency was normalized by using a
gene coding for cytomegalovirus (CMV)-
-Gal as a reporter gene.
rRNA labeling experiments. Equal numbers of APE1-knocked-down,
WTAPE1- and N33APE1-expressing HeLa cells (2  106) were labeled in
medium containing 2.5 Ci/ml [3H]uridine (Perkin-Elmer, Milan, Italy) for 30
min and then chased for the indicated times in label-free medium. Total RNA
was isolated using Trizol reagent and loaded onto 1% (wt/vol) agarose-formal-
dehyde gels. RNA was transferred to Hybond N membranes (GE Healthcare),
cross-linked (150 mJ), sprayed with En3Hance (Perkin-Elmer), and subjected to
autoradiography.
Cell growth assay studies. For proliferation assays, cells were plated in trip-
licate, harvested at the indicated times upon doxycycline treatment, stained with
trypan blue (Sigma), and counted. Colony survival assays were performed as
previously described (41). Briefly, equal numbers (500 cells) of control and
siRNA cells were plated in petri dishes and grown with medium containing or not
containing doxycycline (1 g/ml). On day 10, the medium was removed and
colonies were stained for 2 min with 2 ml of crystal violet solution (10% [wt/vol]
in 70% aqueous ethanol). The dye was then poured off. Then the plates were
rinsed with tap water and allowed to dry. Colonies were counted by using
ImageQuant TL software (GE Healthcare). For each experimental point, the
mean, standard deviation, and statistical significance were calculated from three
independent experiments.
Statistical analysis. Statistical analysis was performed using the Microsoft
Excel data analysis program for Student’s t test analysis. P 0.05 was considered
statistically significant.
RESULTS
Characterization of APE1 interactome map and role of the
protein N-terminal sequence. To avoid stoichiometric prob-
lems due to overexpression of the bait protein and to increase
the efficiency of the immunoprecipitation strategy, we devel-
oped a system in HeLa cells, in which the endogenous APE1
protein was substituted for by an ectopic Flag-tagged recom-
binant WT one. Silencing of the endogenous APE1 was
performed by an inducible siRNA technology through a
doxycycline-responsive promoter (58; and see Fig. S1 in the
supplemental material). Ectopic expression was settled by
stable cloning of an siRNA-resistant cDNA APE1 sequence.
As the endogenous protein, ectopic WT APE1 localized
mainly within the nuclear compartment of HeLa cell clones
and was expressed to a similar extent (see Fig. S1C in the
supplemental material), thus giving reliability to the approach
used. To increase the resolution in the analysis of the immu-
noprecipitated complexes, a 2-DE separation of protein mix-
tures was performed. Figure 1A and Table 1 display the results
of this analysis. As a control, we used immunoprecipitated
material from HeLa cells stably transfected with the empty
vector and expressing a scrambled siRNA sequence (see Ma-
terials and Methods for details and Fig. S2 in the supplemental
material). Interestingly, among the 10 different protein species
that were identified as being part of APE1 complexes (Fig.
1A), five of them (i.e., RLA0, NPM1, MEP50/WDR77, RSSA,
and PRP19) are strictly related to RNA processing and ribo-
some biogenesis. Confirmatory data about interactions were
obtained by coimmunofluorescence analysis (see Fig. S3 in the
supplemental material). In particular, MEP50, K2C8, and
PRDX6 were mainly localized at the cytoplasmic level in the
majority of the cells; PRP19 was exclusively nuclear; and RLA0
displayed a pancellular distribution in both nuclear and cyto-
plasmic compartments.
With the aim of identifying the APE1-interacting partners
modulated by the N-terminal 33 amino acid residues of
the protein, a comparative coimmunoprecipitation analysis
on N33APE1- and WTAPE1-expressing cells was per-
formed. We used the cell system described above, in which
the endogenous APE1 protein was substituted for by an
ectopic Flag-tagged recombinant protein, in both the WT
and N33 deletion mutant forms (see Fig. S1B in the sup-
plemental material). Subcellular distribution of ectopic
N33APE1 resulted in both cytoplasmic and nuclear pro-
teins, as a consequence of the lack of the bipartite NLS
sequence (29) (see Fig. S1C in the supplemental material).
Then, a differential proteomic strategy was used, by per-
forming 2-DE separation of immunoprecipitated protein
mixtures (Fig. 1B). In the N33APE1 interactome map,
particularly evident was the absence of nucleophosmin
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FIG. 1. NPM1 physically interacts with the 33 N-terminal amino acids of APE1. (A) 2-DE gel of the APE1-Flag protein complex immunopurified under
native conditions from HeLa whole-cell lysate (20 mg from 4 107 cells). Results were obtained by silver staining and mass spectrometry identification of the
proteins coimmunopurified with APE1-Flag. Highlighted are all of the proteins interacting specifically with APE1-Flag but not with the anti-Flag antibody.
Names on the 2-DE map correspond to the proteins listed in Table 1. Vertical and horizontal axes indicate apparent molecular mass (kDa) and pI values,
respectively. It has to be noticed that APE1-Flag protein is present in different focalized spots, as the consequence of different posttranslational modifications,
including proteolysis of its N-terminal sequence. (B) 2-DE differential proteomic analysis of coimmunoprecipitated material identifies proteins interacting with
the N-terminal sequence of APE1. Of particular interest was the identification of NPM1, whose interaction is lost upon removal of the first 33 N-terminal amino
acids of APE1. An expanded view of silver-stained gel images of NPM1 shows the loss of interaction with the N33APE1 protein. WT APE1-Flag and
N33APE1-Flag are indicated by one and two asterisks, respectively. (C) Western blotting analysis of the coimmunoprecipitated material. Total cell extracts from
HeLa cells (Mock) and WT APE1 and N33APE1 clones were coimmunoprecipitated. Coimmunoprecipitated material, after normalization for immunopre-
cipitated APE1 protein, was separated by 10% SDS-PAGE and analyzed by Western blotting to evaluate the levels of each interacting partner by using specific
antibodies (shown as -APE1, -NPM1, etc.). In line 1, total cell extract was used as a positive control. Absence of signal in the “Mock” line confirmed the
specificity of the interaction. Moreover, loss of NPM1 signal in the N33 clone validates its interaction with the N-terminal region of APE1. Asterisks indicate
the positions of Ig heavy (*) and light (**) chains used for the immunoprecipitation (IP) procedure, as demonstrated by separate Western blot analysis
performed only with the secondary antibody (data not shown).
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(NPM1 or B23) (Fig. 1B, inset). Validation experiments
with the identified protein species and evaluation of the
effect of the N-terminus truncation on the other interacting
partners identified so far (Fig. 1A) were performed by West-
ern blot analysis on an independent set of immunoprecipi-
tated material (Fig. 1C). Only in the case of MEP50 (Fig.
1C), PRPS1, and PRPS2 (Table 1) was the N-terminal se-
quence dispensable for the interaction with APE1.
APE1 is present within nucleoli and physically interacts
with NPM1. Since NPM1 is a specific nucleolar protein (8), we
inspected whether APE1 localizes within this subnuclear com-
partment. We performed colocalization analysis by immuno-
fluorescence with NPM1 and with another nucleolar marker,
nucleolin (NCL). HeLa cells were fixed, and nucleoli were
visualized by confocal microscopy using antibodies against
NCL or NPM1, which are localized mainly in the dense fibrillar
regions and in the granular component of the nucleolus, re-
spectively (8, 9, 48). Endogenous APE1 was visualized with a
specific monoclonal antibody (39) in the case of colocalization
with NPM1 (Fig. 2A) and with an anti-Flag antibody in the
case of NCL (Fig. 2B). These experiments demonstrated that a
significant portion of nuclear APE1 is concentrated within the
nucleoli, colocalizing with both NCL and NPM1. The gener-
alization of nucleolar localization of APE1 was confirmed by
using several cell lines from different origins (see Fig. S4 in the
supplemental material). A further biochemical validation was
obtained by Western blot analysis of the proteins from purified
HeLa cell nucleoli (38) (Fig. 2C).
Coimmunoprecipitation experiments performed on HeLa
cells transfected with the Flag-tagged APE1 cDNA-encoding
plasmid confirmed the physical interaction between APE1 and
NPM1 and, to a lesser extent, that between APE1 and NCL
(data not shown).
We then checked whether the APE1-NPM1 interaction in-
volves RNA and/or DNA. For this purpose, cell lysates were
digested with nuclease/RNase before coimmunoprecipitation.
While DNase I treatment caused an increased interaction be-
tween the two proteins (possibly as a consequence of the
change in the equilibrium involving APE1 binding to nucleic
acids, which is moved from binding to DNA to binding to RNA
upon treatment with DNase I), treatment with DNase-free
chromatographically purified RNase A mostly reduced it (Fig.
2D; and see Fig. S5 in the supplemental material). The com-
plex containing the two proteins was also dissociated by high
salt concentration (data not shown). These data suggest that
the strong interaction between APE1 and NPM1 may involve
FIG. 2. APE1 is localized within nucleoli of HeLa cells and colocalizes and physically interacts with NPM1 and NCL in the granular region of
the nucleolus. (A) Endogenous APE1 colocalizes with NPM1 in the granular region of the nucleolus. Confocal microscopy of WT HeLa cells fixed
and stained with antibodies against NPM1 (green) and APE1 (red). Overlap of staining (yellow) demonstrated the colocalization of the two
proteins. (B) HeLa cells transfected with the Flag-tagged APE1 cDNA-encoding plasmid were fixed and immunostained for NCL (red) and for
APE1 (green). Merged images (yellow) show the localization of APE1 within nucleoli and colocalization with NCL. The Flag-tagged APE1 protein
was detected with an anti-Flag antibody. (C) The biochemical isolation of nucleoli (37) confirms APE1 localization within these nuclear
substructures (see Materials and Methods for details). Western blot (WB) analysis was performed on 10 g of protein extracts, corresponding to
2 107 cell equivalents for the nucleolar fraction and to 2.5 105 cell equivalents for the nuclear fraction, respectively. -Nucleolin, antinucleolin;
-NPM1, anti-NPM1; -APE1, anti-APE1. (D) The interaction between APE1 and NPM1 is also mediated by RNA. HeLa cells were transfected
with Flag-tagged APE1. Coimmunoprecipitation (IP) was performed using anti-Flag (-Flag) monoclonal antibody-conjugated resin with identical
aliquots of cell lysates. Cell lysates were pretreated with 100 U/ml DNase I and 100 g/ml DNase-free RNase A for 30 min at 30°C before
coimmunoprecipitation. Coimmunoprecipitates were separated onto a 12% SDS-PAGE gel and analyzed by Western blotting with the specific
anti-NPM1 and anti-Flag antibodies.
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RNA molecules and is mediated by electrostatic interactions,
as previously described for the interaction between NCL and
NPM1 (40). Similar data on salt sensitivity and RNA depen-
dence were also obtained for the two cytoplasmic proteins
MEP50 and RLA0 (data not shown).
APE1 nucleolar localization is cell cycle dependent and re-
quires active rRNA transcription. To determine if APE1-
NPM1 interaction is associated with a particular biological
process, we explored for their colocalization during the cell
cycle. Cells were synchronized by the double-thymidine block,
which arrests the cells at the G1/S boundary. Cell samples were
taken at different time points after release, and cell cycle pro-
gression was followed by flow cytometry. Samples were fixed
and examined under a fluorescence microscope. Immediately
after the removal of thymidine, most of the cells are at the G1/S
border. At this time, both APE1 and NPM1 are quite homo-
geneously distributed to the nucleus (Fig. 3A). As the cells
progress through the S phase, 4 h after the double-thymidine
block release, APE1 colocalizes with NPM1 within the nucleoli
in most cells (Fig. 3A). Eleven hours upon release, cells over-
come S phase and are distributed between G2/M and the fol-
lowing G1 phase. Cells in M phase do not show visible nucleoli
according to the nuclear reorganization in mitosis. The cells
shown in Fig. 3A (G2/M-G1) are likely to be in G2 or G1 phase,
since they display a normal morphology. On the contrary, cells
in M phase, which are rounded and weakly attached to the
support, are not represented in this field. Eleven hours upon
release from double-thymidine block, NPM1 is localized in the
nucleoli, whereas APE1 shows a weak nuclear staining with no
evident nucleolar localization. At this particular time point of
release from the block, APE1 seems not to be preferentially
localized in the nucleus, as in the G1/S and S phases, but shows
a diffuse staining with a punctate pattern in the perinuclear
region. The biological significance of this peculiar APE1 local-
ization at this specific point of cell cycle needs to be further
investigated.
rRNA synthesis is mainly exerted during the S phase of the
cell cycle. To evaluate if APE1 remains associated with the
nucleolus in the absence of nascent rRNA transcription, we
treated HeLa cells with ActD, which inhibits transcription by
RNA polymerases I (Pol I), II, and III and causes disruption of
the nucleolus (1), at a final concentration of 1 g/ml and for
different lengths of time. As expected, the disruption of the
nucleolar structure was accompanied by the release of its com-
ponents, as confirmed by the translocation of NPM1 to the
nucleoplasm (Fig. 3B) and the translocation of APE1 in the
perinuclear region. Inhibition of DNA synthesis with hy-
droxyurea did not elicit any effect on the nucleolar localization
of APE1 (see Fig. S6A in the supplemental material), thus
confirming that nucleolar localization of APE1 is specific for
RNA metabolism. In addition, APE1 nucleolar localization
strictly depends on RNA Pol I activity, as demonstrated by
-amanitin treatment at doses (10 g/ml) inhibiting both RNA
Pol II and III but not Pol I (see Fig. S6B in the supplemental
material). Thus, APE1 nucleolar distribution accompanies
rRNA synthesis during cell cycle progression.
The N-terminal homodimerization domain of NPM1 is re-
sponsible for APE1 interaction. We mapped the domain of
NPM1 involved in the interaction with APE1 by GST-pull-
down experiments. Several functional domains have been
mapped in protein NPM1 (Fig. 4A), such as the homodimer-
ization (Fig. 4A) and heterodimerization domains, and the
nucleic acid binding domain (13). We tested the ability of five
deletion mutants of NPM1 to bind APE1 in in vitro pull-down
assays (Fig. 4B). We found that the first 117 N-terminal amino
acid residues were essential for mediating NPM1-APE1 inter-
action. This region, spanning the homodimerization domain, is
responsible for both oligomerization and chaperone activity
of NPM1 (13, 49). Thus, the interaction between APE1 and
NPM1 is largely dependent on the oligomerization domain of
NPM1 and not on its nucleic acid binding region. To confirm
our in vitro GST-pull-down assay experiments in an in vivo cell
context, the two deletion mutants (positions 1 to 186 and 188
to 295) were expressed as Flag-tagged proteins in HeLa cells in
transfection assays. The first mutant showed a nucleoplasmic/
nucleolar localization just like the endogenous NPM1, while
the latter was mislocated, showing mainly a nucleoplasmic lo-
calization, as previously reported (6). Coimmunofluorescence
of endogenous APE1 and Flag-tagged NPM1 deletion mutants
confirmed the GST-pull-down data (Fig. 4C). On the other
hand, transfection of N33APE1 showed no colocalization
with NPM1 in the granular region of nucleoli (Fig. 4D), de-
finitively demonstrating that the APE1 N terminus is involved
in the APE1 subnuclear localization.
APE1 associates with 47S, 28S, and 18S rRNA. In order to
evaluate the ability of APE1 and NPM1 to bind endogenous
rRNA in the cell, we performed coimmunoprecipitation exper-
iments separately for WT APE1, N33APE1, and NPM1. The
enrichment for the 47S, 28S, and 18S rRNA molecules, upon
coimmunoprecipitation, was measured by qRT-PCR analysis
(see Materials and Methods for details and Fig. 5A, left, for
specific positioning of the PCR primers used for amplifica-
tion). As shown in Fig. 5B to D, both WT APE1 and NPM1
were able to bind each of the rRNA molecules tested. Inter-
estingly, the lower ability of the N33APE1 deletion mutant to
bind rRNA, although maintaining the nucleic acid binding
domain at its C-terminal tail, suggested that the APE1 N ter-
minus is required for APE1’s ability to efficiently bind rRNA.
We tested the effect of RNA-binding ability of APE1 on
HeLa cells by immunofluorescence analysis through RNase
FIG. 3. Interaction between APE1 and NPM1 is associated with cell cycle and requires active rRNA transcription. (A) Dynamic interaction of
APE1 and NPM1 during the cell cycle in HeLa cells. HeLa cell cultures were synchronized by double-thymidine treatment. Samples were harvested
either immediately (with most of the cells at the G1/S border) or 4 h (most cells are in S phase) and 11 h after the removal of thymidine (with most
cells distributed among G2/M and the subsequent G1 phases). (B) NPM1 and APE1 translocation induced by ActD. Shown are results obtained
by confocal microscopy of WT HeLa cells fixed and stained with antibodies against NPM1 (green) and APE1 (red). Control cells show a bright
nucleolar fluorescence, which indicates that NPM1 and APE1 are localized within nucleoli. After ActD treatment, the NPM1 nucleoplasmic
fluorescence increased with time, indicating the NPM1 shifted from the nucleoli to the nucleoplasm. At the same time, the nucleolar staining of
APE1 disappeared and the protein appeared to be concentrated in the perinuclear region.
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treatment experiments after permeabilization (32). In control
cells, besides in nucleoli, endogenous APE1 was mainly located
within cellular nuclei (Fig. 5E, 	RNase), in which it colocal-
ized with a chromatin structure protein (i.e., the histone H3
isoform acetylated at Lys18, AcK18-H3). APE1 significantly
relocalized to the cytoplasmic compartment upon RNase treat-
ment (Fig. 5E, RNase), although residual nuclear localiza-
tion was observed. Treatment neither altered the nuclear and
nucleolar structures nor affected DNA integrity, as proven
by AcK18-H3 and NPM1 immunofluorescence (Fig. 5E,
RNase) and DAPI staining (see Fig. S5 in the supplemental
material), thus demonstrating that this effect was due to RNA
binding.
NPM1 stimulates APE1 endonuclease activity on abasic
DNA but inhibits its endonuclease activity on RNA. NPM1 has
chaperone activities on chromatin proteins (49); therefore, we
FIG. 4. Mapping of the APE1-interacting domain in NPM1. Interaction between APE1 and NPM1 requires the homodimerization domain of
NPM1. (A) Domain structure of the full-length GST-NPM1 protein and the various deletion mutants used. HeD, heterodimerization domain;
HoD, homodimerization domain; NBD, nucleic acid binding domain. (B) GST-pulldown assay on recombinant purified APE1 incubated with
equivalent amounts of GST, GST-NPM1, or GST-derivatized deletion mutants. Results were analyzed by SDS-PAGE followed by Western blotting
(WB) analysis with the specific anti-APE1 (-APE1) antibody. -GST, anti-GST. (C) Colocalization of NPM1 mutants with endogenous APE1 in
HeLa cells. Cells were transfected with pcDNA5.1 expression vector containing Flag-tagged WT or mutant NPM1 variants. Ectopic proteins were
detected by immunofluorescence with antibodies to the Flag epitope (green). APE1 was detected by the specific monoclonal antibody (red).
(D) The N33APE1 deletion mutant does not colocalize with NPM1 within nucleoli. HeLa cells were transfected with pcDNA5.1 expression vector
containing the Flag-tagged WT or N33APE1 deletion mutant. Shown are results obtained by confocal microscopy of WT HeLa cells fixed and
stained with antibodies against NPM1 (red) and ectopic Flag-tagged APE1 (green). -Flag, anti-Flag. Overlap of staining (yellow) demonstrates
the colocalization of the two proteins.
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FIG. 5. APE1 associates with 47S, 28S, and 18S rRNA, and NPM1 competes with the binding. (A, left) Schematic representation of the 47S gene
organization and position of the specific primers used for qRT-PCR analysis to quantitate the amount of each of the 47S, 28S, and 18S rRNA molecules present
in the input and in the immunoprecipitated (IP) material of panels B to D. (Right) HeLa cells were transfected with WT APE1-Flag, N33APE1-Flag,
NPM1-Flag, or empty Flag vectors. Coimmunoprecipitation was performed, as described above, after normalization for the total amount of total RNA extracted.
Aliquots of cell lysates and coimmunoprecipitates were used for Western (WB) blot analysis. -Flag, anti-Flag. (B, C, and D) RNAs were extracted from
immunoprecipitated material (as described for panel A, right), and the amounts of 47S, 28S, and 18S rRNA were evaluated by qRT-PCR analysis in the input
and the immunoprecipitated fractions as well. (E) Nuclear localization of APE1 is dependent on the presence of an RNA component. After paraformaldehyde
fixation, Triton X-100-permeabilized HeLa cells were treated with RNase A (RNase) or mock treated (	RNase). Double-labeling immunofluorescence was
carried out using anti-APE1 (-APE1) and anti-AcK18-H3 or anti-NPM1 antibodies. The nuclei, as well as the nucleoli, are not screwed up by RNase treatment
as the stainings of the nuclear component, acetylated H3 histone (AcK18-H3), and of the nucleolar component, NPM1, are preserved.
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tested whether its interaction with APE1 may interfere with
the endonuclease activity of the latter. The assay, as previously
described (64), uses a radiolabeled double-stranded deoxy-
oligonucleotide (26-mer) containing an artificial tetrahydrofu-
ran AP site which, when cleaved by AP endonuclease, pro-
duces a labeled 14-mer. The cleavage activity of a purified
recombinant APE1 (rAPE1) was assayed in the presence/ab-
sence of purified recombinant NPM1 (rNPM1) protein. The
results in Fig. 6A and B show the positive effects of NPM1 on
the APE1 abasic DNA cleavage kinetics. A 10-fold excess of
NPM1, which represents the physiological ratio as calculated
from quantitative biochemical experiments (not shown), in-
creased the APE1 endonuclease activity about threefold (see
Fig. S7 in the supplemental material), thus reinforcing the
physiologic importance of this interaction.
We then evaluated the effects of NPM1 on the cleavage by
APE1 of an ssRNA containing a centrally located abasic site
analogue. APE1 alone was able to incise a radiolabeled abasic
single-stranded 34-mer RNA, ssFRNA (Fig. 6C, left), as recently
demonstrated (5). Differently from what was seen for the abasic
dsDNA, the purified recombinant NPM1 inhibited the rAPE1
endonuclease activity on abasic ssRNA in a concentration-depen-
dent manner (Fig. 6C, right). The inhibition was obtained also in
the presence of the two separated N-terminal (positions 1 to 186)
and C-terminal (positions 188 to 295) domains of NPM1. Elec-
trophoretic mobility shift assay (EMSA) analysis (Fig. 6D) dem-
onstrated that the negative effect of NPM1 on the APE1 endo-
nuclease activity on abasic RNA damage is due to an inhibitory
effect of NPM1 over APE1 binding to ssFRNA. This effect was
also evident in the presence of the N-terminal 1–186 interaction
domain of NPM1, which, however, retained some ability to bind
ssRNA (lane 9). Although experimental limitations prevent us
from drawing any definitive conclusions, the inhibitory effect of
the 188–295 NPM1 deletion mutant on the APE1 endonuclease
activity on ssFRNA could be explained by the ability of this
NPM1 mutant to form higher-order and very stable protein-RNA
complexes, unable to enter the gel (lane 10). In the presence of
full-length NPM1, since the decrease in APE1 binding to
ssFRNA was not followed by a concomitant increase of NPM1/
ssFRNA complex formation (Fig. 6D, lanes 2 to 5), we would
argue that the inhibitory effect of NPM1 over APE1 RNA
binding and RNA endonuclease activity may be explained on
the basis of protein-protein interaction involving NPM1 and
APE1, rather than a competitive squelching effect of NPM1 on
RNA.
The role of APE1 interaction with NPM1 upon its ability to
cleave dsFDNA and ssFRNA was evaluated by performing
enzymatic assays with the N33APE1 purified protein. Figure
6E shows that, as expected, the effect of NPM1 is completely
lost with the N33APE1 endonuclease activity on dsFDNA
(upper) and ssFRNA (lower) (see Fig. S7 in the supplemental
material). Interestingly, the 33 N-terminal residues of APE1
negatively modulate the APE1 endonuclease activity over
dsFDNA, because N33APE1 displays a higher (about 10-
fold) enzymatic activity than the full-length protein (compare
lanes 1 and 4 of Fig. 6E, upper panel; and see Fig. S7 in the
supplemental material). In the case of ssFRNA, N33APE1
shows lower enzymatic activity than the full-length protein
(compare lanes 1 and 4 of Fig. 6E, lower panel). Thus, the
APE1 N terminus is required for APE1 endonuclease activity
on abasic RNA. The disappearance of the higher-order APE1/
ssFRNA complexes, as obtained in the case of the N33APE1
mutant, indicates a role for the N-terminal residues of the
protein in the formation of a stable higher-order complex with
ssFRNA. Overall, these data suggest that while in the case of
dsDNA, NPM1 exerts a stimulatory effect on APE1 endonu-
clease activity over abasic sites, in the case of RNA, NPM1
plays a protective role and that, possibly, recognition of the
abasic substrate, either DNA or RNA, may occur through
different mechanisms. In the case of ssFRNA, this could imply
a role of the nucleic acid’s secondary structure (5).
In order to evaluate whether RNA quality may affect APE1’s
ability to bind it, we performed EMSA experiments with an
intact RNA molecule (called ss34RNA) having the same se-
quence of the ssFRNA but devoid of the abasic site. The
results in Fig. 7A show that while APE1 efficiently binds
ss34RNA (with a dissociation constant of about 2  10	6 M),
the N33APE1 mutant does not. Assays using ss34RNA as
FIG. 6. APE1 endonuclease activity on abasic dsDNA and ssRNA is influenced by interaction with NPM1. (A) NPM1 interaction increases
APE1 endonuclease activity on double-stranded AP DNA (dsFDNA). Reactions were performed as described in Materials and Methods with
homogeneously purified recombinant proteins (rAPE1 and rNPM1) and stopped after 15 min of incubation at 37°C. The conversion of the
radiolabeled tetrahydrofuran-containing oligonucleotide substrate (S) to the shorter incised product (P) was evaluated on a denaturing 20%
(wt/vol) polyacrylamide gel. In each reaction, 2.5 pmol of dsFDNA was used. A representative image from three independent experiments is shown.
F represents the free oligonucleotide probe without addition of enzyme. (B) Endonuclease kinetics of APE1 on dsFDNA is increased by interaction
with NPM1. Reactions were performed as described for panel A, and proteins were incubated for the indicated times and separated on a
denaturing 20% (wt/vol) polyacrylamide gel at 120 V for 2 h. In each reaction, 2.5 pmol of dsFDNA was used. Representative gels are reported
on the left. Average values with standard deviations of three independent experiments are plotted on the right. (C, left) APE1 endonuclease activity
on single-stranded abasic RNA (ssFRNA). Reactions were performed with purified recombinant proteins (rAPE1 and rNPM1) and stopped after
15 min of incubation at 37°C. In each reaction, 2.5 pmol of ssFRNA was used. The conversion of the radiolabeled abasic oligonucleotide substrate
to the shorter incised product was evaluated on a denaturing 20% (wt/vol) polyacrylamide gel. A representative image from three independent
experiments is shown. (Right) NPM1 (and its deletion mutants) inhibits APE1 endonuclease activity on single-stranded abasic ssFRNA. Reactions
were performed and analyzed as described for the left panel. In each reaction, 2.5 pmol of ssFRNA was used. A representative image from three
independent experiments is shown. (D) Binding of APE1 to ssFRNA is competed by NPM1. Reactions were performed with purified recombinant
proteins (rAPE1 and rNPM1). The mixtures were separated on a native (nondenaturing) 8% (wt/vol) polyacrylamide gel at 120 V for 2 h. In each
reaction, 2.5 pmol of ssFRNA was used. A representative EMSA gel image from three independent experiments, using the abasic ssFRNA
sequence, is shown. An asterisk denotes the location of stable APE1-ssFRNA complexes. Two asterisks denote the location of stable NPM1-
ssFRNA complexes. (E) Role of protein-protein interaction with NPM1 on the APE1 endonuclease activity on dsFDNA and ssFRNA. Enzymatic
assays on dsFDNA (upper) and ssFRNA (lower) were performed as described for panels B and C. An asterisk on the lower image indicates the
presence of higher-order stable complexes between WT APE1 and ssFRNA. A representative image from three independent experiments is shown.
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substrate showed that, despite binding to this sequence, APE1
does not have an endonuclease activity on it (Fig. 7B). Thus,
APE1 endonuclease activity on RNA requires the presence of
an abasic site.
Overall, these data reinforce the role of the N terminus in
mediating APE1 binding to RNA in addition to NPM1 and
that the inhibitory effect of NPM1 over APE1 endonuclease
over abasic RNA damage is exerted through mechanisms in-
volving protein-protein interaction.
Loss of endogenous APE1 causes increased rRNA oxidation
and reduces protein synthesis and cell proliferation. The bio-
logical relevance of our in vitro findings was evaluated by
testing the ability to remove damaged (i.e., oxidized) RNA in
cells not expressing APE1 upon oxidative treatment. HeLa
cells were treated for 1 h with 50 or 200 M H2O2 and then
harvested 4 h after treatment. The amount of 8-OHG, the most
abundant oxidized base (18), was evaluated by immunofluo-
rescence analysis using a specific antibody (15A3) that recog-
nizes 8-OHG modification in RNA, as previously reported (10,
46). In H2O2-treated cultures, the intensity of 15A3 immuno-
fluorescence was significantly increased even at the lowest dose
of H2O2 treatment, while being almost undetectable in un-
treated cells (Fig. 8A). Treatment with DNase I to remove
possible immunoreactivity with 8-OHG on DNA, resulted in a
very slight reduction of the signal (not shown). On the
contrary, immunoreactivity was greatly reduced by RNase
treatment, indicating RNA was the major site of nucleic acid
oxidative damage.
Then, control, APE1-knocked-down, and WT APE1-reex-
pressing cells were treated for 1 h with 50 M H2O2. After 4 h
recovery, cells were harvested and RNA was extracted and
purified. The amount of oxidized 18S rRNA molecules was
evaluated by immunoprecipitation with the 15A3 antibody and
quantified by qRT-PCR. Data reported in Fig. 8B (left), as well
as those obtained with the 28S rRNA subunit (not shown),
clearly show that accumulation of oxidized rRNA occurred as
a consequence of APE1 silencing. Northwestern analysis, per-
formed on the same samples of purified RNA, confirmed that
higher levels of 8-OHG were associated with the loss of APE1
expression (Fig. 8B, right). Interestingly, the interaction be-
tween APE1 and NPM1 was reduced by H2O2 treatment, as
demonstrated by coimmunoprecipitation assays (Fig. 8C), sup-
porting the hypothesis that RNA damage modulates its and
APE1’s interaction with NPM1.
Mature and functional (nonoxidized) rRNA molecules are
required for proper ribosome functioning in the protein syn-
thesis processes (15, 26). In addition, mRNA oxidation causes
inefficient elongation and/or premature termination of trans-
lation due to ribosome stalling (45, 53). Thus, we evaluated
whether loss of endogenous APE1 may have any effect on the
cellular protein translation processes. Comparison of the total
protein content in cells lacking endogenous APE1 with that of
control cells or cells reexpressing ectopic Flag-tagged WT
APE1 (Fig. 8D, left) revealed that loss of APE1 caused a
significant inhibition of protein translation processes. The re-
sults obtained by reporter assay experiments with in vitro-
transcribed luciferase mRNA in APE1-deficient cells (Fig. 8D,
right) strongly confirmed that the translation impairment fol-
lowing APE1 silencing is due to posttranscriptional mecha-
nisms.
It is known that NPM1 is involved in ribosome biogenesis
(27). Thus, considering (i) the interaction between APE1 and
NPM1, (ii) the observed correlation between rRNA synthesis
and APE1 localization, and (iii) the effect of APE1 silencing on
protein synthesis, we asked whether the presence of APE1 or
N33APE1 could affect rRNA synthesis. Knocked-down HeLa
cells, as well as WT APE1- and N33APE1-expressing cells,
were pulse-labeled with [3H]uridine and chased for 30, 60, and
120 min to analyze the kinetics of newly synthesized rRNA.
Then, their RNA was extracted and analyzed on gel (Fig. 8E).
The pulse-labeled 47S rRNA precursor was readily detected in
all samples at the beginning of chasing (0 min), indicating that
transcription of the rRNA precursor was not blocked by APE1
downregulation. At the 60-min time point, the amount of ma-
ture 28S rRNA was approximately equal to the amount of 32S
intermediate in all cell lines, with a 28S/32S ratio of approxi-
mately equal to 1. These data, showing that downregulation of
APE1 or expression of the truncated protein did not alter the
kinetics of rRNA processing but possibly led to formation of
nonfunctional ribosomes, strongly suggest that APE1-NPM1
interaction may be part of a more general rRNA quality con-
trol process.
We then evaluated how the loss of APE1 functions in the
FIG. 7. APE1 efficiently binds but does not cleave the intact
ss34RNA oligonucleotide. (A) Reactions were performed with puri-
fied recombinant proteins (rAPE1 and rN33-APE1) and separated as
described in the legend to Fig. 6D. ss34RNA is an intact oligonucle-
otide bearing the same sequence of ssFRNA but devoid of the abasic
site. In each reaction, 2.5 pmol of intact ss34RNA was used. A repre-
sentative EMSA gel image, from three independent experiments, is
shown. F represents the free oligonucleotide probe without addition of
enzyme. (B) APE1 does not cleave a single-stranded intact RNA
(ss34RNA). Reactions were performed and separated as described for
Fig. 6C. In each reaction, 2.5 pmol of ss34RNA or ssFRNA was used,
as indicated.
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RNA-related process influences cell proliferation and via-
bility. Cell counting and colony survival assays showed that
N33APE1-expressing cells displayed a significantly lower cell
growth rate than WT APE1-expressing cells (Fig. 8F) and an
intermediate growth rate compared with APE1-silenced cells.
To define the impact of N33APE1 expression on cell growth,
we characterized cell cycle and apoptosis in reconstituted cells.
Cell cycle characterization was performed through FACS anal-
ysis. Loss of APE1 impairs the passage from the S to G2/M
phases to the following G1 phase, as measured by increase in S
to G2/M phases versus the G1 population ratio (58). On the
contrary, reconstituted cells did not show any significant dif-
ference between WT APE1- and N33APE1-expressing cells
(not shown). Cell death was characterized through apoptosis-
specific assays (i.e., annexin V staining and caspase 3/7 activa-
tion). Both assays clearly demonstrated that cells expressing
N33APE1 show an increased apoptotic rate compared with
WT APE1-expressing cells (Fig. 8G). Therefore, we can con-
clude that differences in cell growth between WT APE1- and
N33APE1-expressing cells are mainly due to increased death
of the latter cells.
DISCUSSION
In this work, we have identified some of the APE1 interac-
tome components under physiological cellular conditions, tak-
ing advantage of the cell system we developed in which endog-
enous APE1, silenced by the inducible expression of specific
siRNA sequences, was replaced by a comparable amount of an
ectopic siRNA-resistant Flag-tagged protein. Ten different
proteins, among which was NPM1, mostly associated with
RNA maturation and processing, were identified by proteomic
analysis. We then focused our attention on the APE1/NPM1
complex and on the role played by this interaction in regulating
APE1 endonuclease activity on abasic DNA or RNA and in the
process of ribosome biogenesis and cell growth. We found an
unsuspected role of APE1 in the rRNA quality control process
that may open new perspectives in the comprehension of the
nuclear and extranuclear functions of this protein, with a sig-
nificant impact on human pathological processes such as neu-
rodegenerative diseases and cancer.
Interestingly, we found that the first 33 N-terminal amino
acids of APE1 are essential for stabilizing the interaction of
APE1 with most of the identified partners, except MEP50,
PRPS1, and PRPS2 (Table 1). While the C-terminal part of the
protein is highly conserved during phylogeny, the N terminus is
not (55, 56). Besides the mammalian proteins, in which the N
terminus is highly conserved, this region is almost absent in
other organisms, thus suggesting that it may represent a recent
gain of function during evolution (55, 56). Based on our data
and the awareness that this N-terminal sequence can be
cleaved off under cellular stress conditions (11, 16, 23, 29, 66),
we can infer that the unstructured amino-terminal sequence of
APE1 is devoted to fine-tuning the different functions of
APE1, mainly through modulation of its interactome network.
The increased endonuclease activity, over abasic dsDNA, of
N33APE1 with respect to the full-length protein (Fig. 6E)
and the observation that the APE1 N-terminal sequence is
indispensable for its stable binding to RNA (Fig. 7A) further
support the hypothesis that the N-terminal arm acts as a func-
tional “switch” for modulating some of the different APE1
activities in mammalian cells.
A further important aspect resulting from this study is the
subnuclear localization of APE1 within nucleoli as a conse-
quence of the interaction with NPM1 and with the rRNA
production process. Since rRNA synthesis and processing
mostly occur at the G1/S phase, compartmentalization of APE1
to the nucleoli during the S phase might increase the efficiency
of ribosomal DNA (rDNA) transcription, through its BER
activity, and/or the cleavage of abasic damaged rRNA mole-
cules. In fact, APE1 is involved in the formation of a complex
comprising NPM1 as well as precursor (47S) and mature (18S
and 28S) rRNA molecules. Our EMSA experiments with pu-
rified recombinant APE1 protein suggest that APE1 may bind
rRNA independently of NPM1 binding and that the N-termi-
nal region is required for stable interaction with RNA mole-
cules both in vivo (Fig. 5B to D) and in vitro (Fig. 7A).
Interaction with NPM1 in vitro stimulates APE1 endonucle-
ase activity over abasic DNA, while it inhibits that on abasic
RNA. What is the biological meaning of these results? Based
on (i) the ability of NPM1 to stably bind to RNA but not to
abasic dsDNA (not shown), (ii) the similar affinities of NPM1
and APE1 for abasic RNA (Fig. 6D, lane 3), and (iii) the
presence of about 10-fold molar excess of NPM1 with respect
to APE1 within nucleoli (not shown), it is conceivable that
NPM1 may exert a fine-tuning control of APE1 endonuclease
activity within nucleoli devoted to repair of AP damage on
rDNA and the removal of oxidized rRNA molecules. Experi-
ments are now in progress to demonstrate this possibility.
Based on our experimental data, we believe that the inhib-
itory effect of NPM1 over APE1 endonuclease activity on RNA
may be explained on the basis of protein-protein interaction. In
the absence of RNA damage, APE1 and NPM1 could be as-
sociated with RNA molecules. In the presence of an excess of
NPM1 or a switching mechanism (such as a posttranslational
modifications affecting APE1 N-terminus and/or NPM1) in-
creasing the interaction between APE1 and NPM1, APE1
could be titrated away from RNA binding by NPM1, because
the latter protein can mask the APE1 domain responsible for
RNA binding. Alternatively, in the presence of an AP site
formed on RNA, interaction between APE1 and NPM1 and/or
NPM1 and RNA is weakened and APE1 may bind with in-
creased affinity to the target RNA. The mode of NPM1 binding
to RNA seems to be affected by RNA quality (abasic RNA is
bound differently from undamaged RNA; data not shown);
thus, NPM1 could be displaced from RNA binding. Therefore,
competition of RNA and NPM1 for binding to APE1 N-ter-
minal sequence may control the final outcome. Experiments
are currently in progress to clarify this issue.
This picture does not hide the paramount role of APE1 on
the RNA quality control process. The experimental data on
support of this role are (i) the APE1 capacity of cleaving abasic
RNA (5) (Fig. 6C, left), (ii) the accumulation of oxidized
rRNA on APE1-defective cells (Fig. 8B), and (iii) the de-
creased APE1-NPM1 interaction in H2O2-damaged HeLa cells
(Fig. 8C). Where and when the RNA cleansing process is
carried out by APE1 depends on the relative local amounts of
APE1 and NPM1 and on the extent of damage present in
rRNA and rDNA within nucleoli. By this hypothesis, the
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NPM1 affinity for damaged rRNA should diminish, whereas
that of APE1 should increase with the extent of damage.
Why do APE1-defective cells have increased 8-OHG rRNA
content upon oxidative stress? This can be explained only as-
suming that, besides spontaneous generation (31), enzymatic
generation of abasic sites occurs upon rRNA oxidation. The
existence of specific N-ribohydrolases, including the toxin ricin,
has been already documented (44). A role for the YB-1 protein
in recognizing 8-OHG sites has also been hypothesized (24),
but no specific enzymatic mechanisms able to remove the ox-
idized base have been described yet. The accumulation of the
8-OHG substrates, which occurs upon silencing of APE1 ex-
pression, may thus be explained under the assumption that
enzymatic removal of oxidized RNA bases represents the lim-
iting step in the process. Interestingly, as hypothesized for
DNA substrates, APE1 could be stimulating a glycosylase ac-
tivity by allowing a faster turnover (61). Even though, due to
the lack of a reliable method, we did not quantify the amount
of abasic RNA damage, it is reasonable to postulate that in
APE1-depleted cells the abasic RNA damage may also be
increased as is abasic DNA damage (20, 58). Work is now
undergoing to clarify these issues.
Due to its intrinsic nature (i.e., mostly single stranded and
with bases not protected by hydrogen bonding or binding to
specific proteins) and to its relative larger amount, RNA may
be more susceptible to oxidative insults than DNA (36). Not
only 8-OHG but also 5-hydroxycytidine, 5-hydroxyuridine, and
8-hydroxyadenosine have been identified in oxidized RNA
(65). If not repaired, these kinds of damage causing altered
pairing may lead to ribosomal dysfunctions and erroneous
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FIG. 8. Loss of endogenous APE1 causes increased rRNA oxidation and reduces protein synthesis and cell proliferation. (A) RNA oxidation occurs
in H2O2-treated cells. HeLa cells were exposed to the indicated doses of H2O2 for 1 h, followed by a recovery period of 4 h. RNA oxidation was detected
by 15A3 immunofluorescence staining. The immunoreactivity was greatly diminished by the RNase treatment. All samples were DNase I treated.
(B) Accumulation of oxidatively damaged rRNA in APE1-knocked-down cells. (Left) Quantitative analysis of the amount of rRNA oxidation in
15A3-immunoprecipitated RNAs by qRT-PCR analysis. Control represents HeLa cells stably transfected with a scrambled shRNA sequence (siScr),
siAPE1 represents HeLa cells stably transfected with a specific shRNA sequence to inhibit endogenous APE1 expression, WT APE1 represents cells
expressing only the ectopic APE1 protein in spite of the endogenous one (see Materials and Methods) (58). Inducible silencing of endogenous APE1
was obtained through doxycycline (1 g/ml) treatment for 10 days as described in Materials and Methods and reference 58. HeLa cells (2  106) were
treated for 1 h with 50 M H2O2 and released for 4 h. Analysis of 8-OHG-containing RNA is described in Materials and Methods. Levels of oxidation
(ox) of 18 S rRNA are higher in APE1-silenced than in APE1-expressing cells, supporting the hypothesis that APE1 plays a role in cleansing of damaged
RNA within mammalian cells. Data are means  standard deviations from three independent experiments. *, P  0.05. (Right) 15A3 antibody-based
dot blot Northwestern detection of 8-OHG was used to analyze the amount of oxidized RNA in the total RNA pool from expressing and nonexpressing
HeLa cells, treated as described above. As a loading control, the bands corresponding to 28S and 18S rRNA were visualized by ethidium bromide staining
of the gel before transfer. In vitro oxidation of purified RNA with different amounts of H2O2 was used to demonstrate the specificity of the assay used.
(C) RNA oxidation impairs APE1-NPM1 interaction. Coimmunoprecipitation (IP) experiments were performed on HeLa cells stably expressing WT
APE1-Flag or N33APE1-Flag proteins and treated as described for panel B. Then the presence of NPM1 protein in the immunoprecipitated material
was evaluated by Western blotting (WB). -Flag, anti-Flag; -NMP1, anti-NMP1. (D, left) After 10 days of doxycycline treatment, HeLa cells (5  105)
were harvested and analyzed for protein content by a standard colorimetric Bradford assay. HeLa cell clones were as described for panel 8B. (Right)
Control (siScr) or nonexpressing (siAPE1) endogenous APE1 HeLa cells were transfected with in vitro-transcribed luciferase mRNA. Normalized
luciferase activity as a function of the total protein levels is reported. Experimental details are described in Materials and Methods. The endogenous level
of APE1 protein was evaluated by Western blot analysis on the total cell extract. -APE1, anti-APE1. Data, expressed as the change (fold) with respect
to control cultures, are means standard deviations from three independent experiments. *, P 0.05. (E) Silencing (siAPE1) or expression of truncated
APE1 (N33APE1) does not affect rRNA synthesis as determined by pulse-chase experiments. HeLa cells as control cells (siScr), nonexpressing cells
(siAPE1), or cells expressing only the WT or APE1 deletion mutant (N33APE1) were obtained as described in Materials and Methods and reference
58 and treated with doxycycline (1 g/ml) for 10 days. Then the cells were pulse-labeled with [3H]uridine for 30 min and chased for the indicated times.
An equal amount of RNA was loaded into each lane. The ratios of densitometric signals of 28S to 32S, calculated by a PhosphorImager, are shown.
(F) Effect of APE1 silencing on cell proliferation and role of the N-terminal 33-amino-acid sequence. HeLa cell clones were as described for panel E.
Cells were treated for different times with doxycycline (1 g/ml), and then cell growth was measured. (Left) Growth was monitored through direct cell
counting by measuring the cell number at various times after doxycycline (Doxy) treatment. Data are means  standard deviations from three
independent experiments. *, P 0.05. (Right) Cell growth as measured by colony survival assay. Five hundred cells of the control and siRNA clones were
seeded in petri dishes and then treated with doxycycline for 10 days. Data, expressed as the percentage of change with respect to control cultures, are
means standard deviations from three independent experiments. *, P 0.05. (G) Loss of the 33 N-terminal amino acids within APE1 sequence affects
cell death. HeLa cell clones were as described for panel E. Apoptosis was measured through caspase 3/7 activation (left) and annexin V (right) assays.
The histograms show the average  standard deviation of the fluorescence values (relative fluorescence units [RFU]) obtained from three independent
experiments. *, P  0.05.
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translation process, thus significantly affecting the overall pro-
tein synthesis mechanism (15, 53). In agreement with this hy-
pothesis, we found a significant reduction in the protein syn-
thesis rate upon silencing of APE1 expression (Fig. 8D). RNA
damage, in turn, causes cell cycle arrest and cell death, with or
without the contribution of p53 and inhibition of protein syn-
thesis (4). From our data, the RNA-binding function of APE1,
which is specifically controlled through interaction by means of
its N-terminal sequence, seems to have a significant impact on
cell viability (Fig. 8F and G).
The new and striking findings of APE1 interaction with
RNA and with proteins involved in ribosome assembly (i.e.,
RLA0 and RSSA) and RNA maturation (i.e., PRP19 and
MEP50) within cytoplasm could also represent a molecular
explanation for the “extranuclear” functions of this protein. Its
RNA-mediated association with these proteins would rein-
force the hypothesis of APE1 as an essential factor in the RNA
quality control process. Future studies will elucidate whether
this hypothesis could also explain the cytoplasmic accumula-
tion of APE1 in a number of tumor cell types (55, 56).
Oxidative damage to RNA molecules, both coding for pro-
teins (mRNA) or performing translation (rRNA and tRNA),
has recently been associated with the occurrence of neurode-
generative diseases such as Alzheimer’s disease (36) and its
impact in cancer development could not be excluded, at
present (4). Thus, all of the hypotheses made about the in-
FIG. 8—Continued.
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volvement of APE1 in the development of such pathologies
should be reinterpreted in light of our findings. The role that
APE1 has in RNA-related processes needs further study, but
due to its ability to recognize and cleave through its endonu-
clease activity the RNA AP sites (see our present data and
reference 5), its role is compatible with a leading role in the
early stages of the RNA quality control process. Little infor-
mation is still available on the molecular mechanisms respon-
sible for specific recognition and removal of damaged RNA
(4), in particular abasic RNA. Our data clearly point to APE1
as a novel enzyme responsible for the “cleansing” process to
degrade and remove the abasic RNA molecules, which may
play a leading role in the control of RNome functionality, in
association with hAlkB and YB-1.
ACKNOWLEDGMENTS
This work was supported by grants from MIUR (FIRB RBRN
07BMCT and the Italian Human Proteome Network) and Telethon
(GGP06268) to G.T. and CNR (AG.P04.015, MERIT, and RSTL 862)
to A.S.
We greatly thank Sankar Mitra for fundamental support in the
development of this work.
REFERENCES
1. Andersen, J. S., Y. W. Lam, A. K. L. Leung, S. E. Ong, C. E. Lyon, A. I.
Lamond, and M. Mann. 2005. Nucleolar proteome dynamics. Nature 433:
77–83.
2. Apicelli, A. J., L. B. Maggi, Jr., A. C. Hirbe, A. P. Miceli, M. E. Olanich, C. L.
Schulte-Winkeler, A. J. Saporita, M. Kuchenreuther, J. Sanchez, K. Weil-
baecher, and J. D. Weber. 2008. A non-tumor suppressor role for basal
p19ARF in maintaining nucleolar structure and function. Mol. Cell. Biol.
28:1068–1080.
3. Beernink, P. T., B. W. Segelke, M. Z. Hadi, J. P. Erzberger, D. M. Wilson III,
and B. Rupp. 2001. Two divalent metal ions in the active site of a new crystal
form of human apurinic/apyrimidinic endonuclease, Ape1: implications for
the catalytic mechanism. J. Mol. Biol. 307:1023–1034.
4. Bellacosa, A., and E. G. Moss. 2003. RNA repair: damage control. Curr.
Biol. 13:R482–R484.
5. Berquist, B. R., D. R. McNeill, and D. M. Wilson III. 2008. Characterization
of abasic endonuclease activity of human Ape1 on alternative substrates, as
well as effects of ATP and sequence context on AP site incision. J. Mol. Biol.
379:17–27.
6. Bertwistle, D., M. Sugimoto, and C. J. Sherr. 2004. Physical and functional
interactions of the Arf tumor suppressor protein with nucleophosmin/B23.
Mol. Cell. Biol. 24:985–996.
7. Bhakat, K. K., T. Izumi, S. H. Yang, T. K. Hazra, and S. Mitra. 2003. Role
of acetylated human AP-endonuclease (APE1/Ref-1) in regulation of the
parathyroid hormone gene. EMBO J. 1:6299–6309.
8. Biggiogera, M., S. Fakan, S. H. Kaufmann, A. Black, J. H. Shaper, and H.
Busch. 1989. Simultaneous immunoelectron microscopic visualization of
protein B23 and C23 distribution in the HeLa cell nucleolus. J. Histochem.
Cytochem. 37:1371–1374.
9. Chan, P. K., W. Y. Chan, B. Y. Yung, R. G. Cook, M. B. Aldrich, D. Ku, I. L.
Goldknopf, and H. Busch. 1986. Amino acid sequence of a specific antigenic
peptide of protein B23. J. Biol. Chem. 261:14335–14341.
10. Chang, Y., Q. Kong, X. Shan, G. Tian, H. Ilieva, D. W. Cleveland, J. D.
Rothstein, D. R. Borchelt, P. C. Wong, and C. L. Lin. 2008. Messenger RNA
oxidation occurs early in disease pathogenesis and promotes motor neuron
degeneration in ALS. PLoS ONE. 3:e2849.
11. Chattopadhyay, R., L. Wiederhold, B. Szczesny, I. Boldogh, T. K. Hazra, T.
Izumi, and S. Mitra. 2006. Identification and characterization of mitochon-
drial abasic (AP)-endonuclease in mammalian cells. Nucleic Acids Res.
34:2067–2076.
12. Chung, U., T. Igarashi, T. Nishishita, H. Iwanari, A. Iwamatsu, A. Suwa, T.
Mimori, K. Hata, S. Ebisu, E. Ogata, T. Fujita, and T. Okazaki. 1996. The
interaction between Ku antigen and REF1 protein mediates negative gene
regulation by extracellular calcium. J. Biol. Chem. 271:8593–8598.
13. Colombo, E., J. C. Marine, D. Danovi, B. Falini, and P. G. Pelicci. 2002.
Nucleophosmin regulates the stability and transcriptional activity of p53.
Nat. Cell Biol. 4:529–533.
14. Ding, Q., E. Dimayuga, W. R. Markesbery, and J. N. Keller. 2004. Protea-
some inhibition increases DNA and RNA oxidation in astrocyte and neuron
cultures. J. Neurochem. 91:1211–1218.
15. Ding, Q., W. R. Markesbery, Q. Chen, F. Li, and J. N. Keller. 2005. Ribo-
some dysfunction is an early event in Alzheimer’s disease. J. Neurosci.
25:9171–9175.
16. Fan, Z., P. J. Beresford, D. Zhang, Z. Xu, C. D. Novina, A. Yoshida, Y.
Pommier, and J. Lieberman. 2003. Cleaving the oxidative repair protein
Ape1 enhances cell death mediated by granzyme A. Nat. Immunol. 4:145–
153.
17. Fantini, D., C. Vascotto, M. Deganuto, N. Bivi, S. Gustincich, G. Marcon, F.
Quadrifoglio, G. Damante, K. K. Bhakat, S. Mitra, and G. Tell. 2008.
APE1/Ref-1 regulates PTEN expression mediated by Egr-1. Free Radic.
Res. 42:20–29.
18. Fiala, E. S., C. C. Conaway, and J. E. Mathis. 1989. Oxidative DNA and
RNA damage in the livers of Sprague-Dawley rats treated with the hepato-
carcinogen 2-nitropropane. Cancer Res. 49:5518–5522.
19. Frehlick, L. J., J. M. Eirìn-Lo`pez, and J. Ausio`. 2007. New insights into the
nucleophosmin/nucleoplasmin family of nuclear chaperones. Bioessays 29:
49–59.
20. Fung, H., and B. Demple. 2005. A vital role for Ape1/Ref1 protein in
repairing spontaneous DNA damage in human cells. Mol. Cell 17:463–470.
21. Gorman, M. A., S. Morera, D. G. Rothwell, E. de La Fortelle, C. D. Mol, J. A.
Tainer, I. D. Hickson, and P. S. Freemont. 1997. The crystal structure of the
human DNA repair endonuclease HAP1 suggests the recognition of extra-
helical deoxyribose at DNA abasic sites. EMBO J. 16:6548–6558.
22. Grillo, C., C. D’Ambrosio, A. Scaloni, M. Maceroni, S. Merluzzi, C. Turano,
and F. Altieri. 2006. Cooperative activity of Ref-1/APE and ERp57 in re-
ductive activation of transcription factors. Free Radic. Biol. Med. 41:1113–
1123.
23. Guo, Y., J. Chen, T. Zhao, and Z. Fan. 2008. Granzyme K degrades the
redox/DNA repair enzyme Ape1 to trigger oxidative stress of target cells
leading to cytotoxicity. Mol. Immunol. 45:2225–2235.
24. Hayakawa, H., T. Uchiumi, T. Fukuda, M. Ashizuka, K. Kohno, M. Kuwano,
and M. Sekiguchi. 2002. Binding capacity of human YB-1 protein for RNA
containing 8-oxoguanine. Biochemistry 41:12739–12744.
25. He, T., N. L. Weintraub, P. C. Goswami, P. Chatterjee, D. M. Flaherty, F. E.
Domann, and L. W. Oberley. 2003. Redox factor-1 contributes to the regu-
lation of progression from G0/G1 to S by PDGF in vascular smooth muscle
cells. Am. J. Physiol. Heart Circ. Physiol. 285:804–812.
26. Honda, K., M. A. Smith, X. Zhu, D. Baus, W. C. Merrick, A. M. Tartakoff,
T. Hattier, P. L. Harris, S. L. Siedlak, H. Fujioka, Q. Liu, P. I. Moreira, F. P.
Miller, A. Nunomura, S. Shimohama, and G. Perry. 2005. Ribosomal RNA
in Alzheimer disease is oxidized by bound redox-active iron. J. Biol. Chem.
280:20978–20986.
27. Itahana, K., K. P. Bhat, A. Jin, Y. Itahana, D. Hawke, R. Kobayashi, and Y.
Zhang. 2003. Tumor suppressor ARF degrades B23, a nucleolar protein
involved in ribosome biogenesis and cell proliferation. Mol. Cell 12:1151–
1164.
28. Izumi, T., D. B. Brown, C. V. Naidu, K. K. Bhakat, M. A. Macinnes, H. Saito,
D. J. Chen, and S. Mitra. 2005. Two essential but distinct functions of the
mammalian abasic endonuclease. Proc. Natl. Acad. Sci. USA 102:5739–5743.
29. Jackson, E. B., C. A. Theriot, R. Chattopadhyay, S. Mitra, and T. Izumi.
2005. Analysis of nuclear transport signals in the human apurinic/apyrimidi-
nic endonuclease (APE1/Ref1). Nucleic Acids Res. 33:3303–3312.
30. Kuninger, D. T., T. Izumi, J. Papaconstantinou, and S. Mitra. 2002. Human
AP-endonuclease 1 and hnRNP-L interact with a nCaRE-like repressor
element in the AP-endonuclease 1 promoter. Nucleic Acids Res. 30:823–829.
31. Loeb, L. A., and B. D. Preston. 1986. Mutagenesis by apurinic/apyrimidinic
sites. Annu. Rev. Genet. 20:201–230.
32. Maison, C., D. Bailly, A. Peters, J. P. Q. Quivy, D. Roche, A. Taddei, M.
Lachner, T. Jenuwein, and G. Almouzni. 2002. Higher-order structure in
pericentric heterochromatin involves a distinct pattern of histone modifica-
tion and an RNA component. Nat. Genet. 30:329–334.
33. Mitra, S., T. Izumi, I. Boldogh, K. K. Bhakat, R. Chattopadhyay, and B.
Szczesny. 2007. Intracellular trafficking and regulation of mammalian AP-
endonuclease 1 (APE1), an essential DNA repair protein. DNA Repair
(Amsterdam) 6:461–469.
34. Mittal, V. 2004. Improving the efficiency of RNA interference in mammals.
Nat. Rev. Genet. 5:355–365.
35. Mol, C. D., T. Izumi, S. Mitra, and J. A. Tainer. 2000. DNA-bound structures
and mutants reveal abasic DNA binding by APE1 and DNA repair coordi-
nation. Nature 403:451–456.
36. Moreira, P. I., A. Nunomura, M. Nakamura, A. Takeda, J. C. Shenk, G.
Aliev, M. A. Smith, and G. Perry. 2008. Nucleic acid oxidation in Alzheimer
disease. Free Radic. Biol. Med. 44:1493–1505.
37. Muramatsu, M., K. Smetana, and H. Busch. 1963. Quantitative aspects of
isolation of nucleoli of the Walker carcinosarcoma and liver of the rat.
Cancer Res. 25:693–697.
38. Parlanti, E., G. Locatelli, G. Maga, and E. Dogliotti. 2007. Human base
excision repair complex is physically associated to DNA replication and cell
cycle regulatory proteins. Nucleic Acids Res. 35:1569–1577.
39. Pines, A., L. Perrone, N. Bivi, M. Romanello, G. Damante, M. Gulisano,
M. R. Kelley, F. Quadrifoglio, and G. Tell. 2005. Activation of APE1/Ref-1
is dependent on reactive oxygen species generated after purinergic receptor
stimulation by ATP. Nucleic Acids Res. 33:4379–4394.
VOL. 29, 2009 APE1 FUNCTIONALLY INTERACTS WITH NPM1 1853
 o
n
 July 25, 2014 by Ruth Lilly M
edical Library
http://m
cb.asm
.org/
D
ow
nloaded from
 
40. Pin˜ol-Roma, S. 1999. Association of nonribosomal nucleolar proteins in
ribonucleoprotein complexes during interphase and mitosis. Mol. Biol. Cell
10:77–90.
41. Plumb, J. A. 1999. Cell sensitivity assays: clonogenic assay. Cytotoxic drug
resistance mechanisms. Humana Press, Totowa, NJ.
42. Reardon, B. J., C. R. Lombardo, and M. Sander. 1998. Drosophila Rrp1
domain structure as defined by limited proteolysis and biophysical analyses.
J. Biol. Chem. 273:33991–33999.
43. Savkur, R. S., and M. O. Olson. 1998. Preferential cleavage in pre-ribosomal
RNA byprotein B23 endoribonuclease. Nucleic Acids Res. 26:4508–4515.
44. Schramm, V. L. 1997. Enzymatic N-riboside scission in RNA and RNA
precursors. Curr. Opin. Chem. Biol. 1:323–331.
45. Shan, X., H. Tashiro, and C. L. Lin. 2003. The identification and character-
ization of oxidized RNAs in Alzheimer’s disease. J. Neurosci. 23:4913–4921.
46. Shan, X., Y. Chang, and C. L. Lin. 2007. Messenger RNA oxidation is an
early event preceding cell death and causes reduced protein expression.
FASEB J. 21:2753–2764.
47. Shevchenko, A., M. Wilm, O. Vorm, and M. Mann. 1996. Mass spectrometric
sequencing of proteins silver-stained polyacrylamide gels. Anal. Chem. 68:
850–858.
48. Srivastava, M., P. J. Fleming, H. B. Pollard, and A. L. Burns. 1989. Cloning
and sequencing of the human nucleolin cDNA. FEBS Lett. 250:99–105.
49. Swaminathan, V., A. H. Kishore, K. K. Febitha, and T. K. Kundu. 2005.
Human histone chaperone nucleophosmin enhances acetylation-dependent
chromatin transcription. Mol. Cell. Biol. 25:7534–7545.
50. Szczesny, B., and S. Mitra. 2005. Effect of aging on intracellular distribution
of abasic (AP) endonuclease 1 in the mouse liver. Mech. Ageing Dev.
126:1071–1078.
51. Szebeni, A., K. Hingorani, S. Negi, and M. O. Olson. 2003. Role of protein
kinase CK2 phosphorylation in the molecular chaperone activity of nucleolar
protein b23. J. Biol. Chem. 278:9107–9115.
52. Takeuchi, R., T. Ruike, R. Nakamura, K. Shimanouchi, Y. Kanai, Y. Abe, A.
Ihara, and K. Sakaguchi. 2006. Drosophila DNA polymerase zeta interacts
with recombination repair protein 1, the Drosophila homologue of human
abasic endonuclease 1. J. Biol. Chem. 281:11577–11585.
53. Tanaka, M., P. B. Chock, and E. R. Stadtman. 2007. Oxidized messenger
RNA induces translation errors. Proc. Natl. Acad. Sci. USA 104:66–71.
54. Tell, G., E. Crivellato, A. Pines, I. Paron, C. Pucillo, G. Mancini, A. Ban-
diera, M. R. Kelley, C. Di Loreto, and G. Damante. 2001. Mitochondrial
localization of APE/Ref-1 in thyroid cells. Mutat. Res. 485:143–152.
55. Tell, G., F. Quadrifoglio, C. Tiribelli, and M. R. Kelley. 2009. The many
functions of APE1/Ref-1: not only a DNA-repair enzyme. Antioxid. Redox
Signal. [Epub ahead of print.] doi:10.1089/ars.2008.2194.
56. Tell, G., G. Damante, D. Caldwell, and M. R. Kelley. 2005. The intracellular
localization of APE1/Ref-1: more than a passive phenomenon? Antioxid.
Redox Signal. 7:367–384.
57. van de Wetering, M., I. Oving, V. Muncan, M. T. Pon Fong, H. Brantjes, D.
van Leenen, F. C. Holstege, T. R. Brummelkamp, R. Agami, and H. Clevers.
2003. Specific inhibition of gene expression using a stably integrated, induc-
ible small-interfering-RNA vector. EMBO Rep. 4:609–615.
58. Vascotto, C., L. Cesaratto, L. A. H. Zeef, M. Deganuto, C. D’Ambrosio, A.
Scaloni, M. Romanello, G. Damante, G. Taglialatela, D. Delneri, M. R.
Kelley, S. Mitra, F. Quadrifoglio, and G. Tell. 29 January 2009. Genome-
wide analysis and proteomic studies reveal APE1/Ref-1 multifunctional role
in mammalian cells. Proteomics [Epub ahead of print.] doi:10.1002/
pmic.200800638.
59. Vascotto, C., L. Cesaratto, C. D’Ambrosio, A. Scaloni, C. Avellini, I. Paron,
U. Baccarani, G. L. Adani, C. Tiribelli, F. Quadrifoglio, and G. Tell. 2006.
Proteomic analysis of liver tissues subjected to early ischemia/reperfusion
injury during human orthotopic liver transplantation. Proteomics 6:3455–
3465.
60. Vidal, A. E., S. Boiteux, I. D. Hickson, and J. P. Radicella. 2001. XRCC1
coordinates the initial and late stages of DNA abasic site repair through
protein-protein interactions. EMBO J. 20:6530–6539.
61. Vidal, A. E., I. D. Hickson, S. Boiteux, and J. P. Radicella. 2001. Mechanism
of stimulation of the DNA glycosylase activity of hOGG1 by the major
human AP endonuclease: bypass of the AP lyase activity step. Nucleic Acids
Res. 29:1285–1292.
62. Wilson, D. M., III. 2003. Properties of and substrate determinants for the
exonuclease activity of human apurinic endonuclease Ape1. J. Mol. Biol.
330:1027–1037.
63. Xanthoudakis, S., G. G. Miao, and T. Curran. 1994. The redox and DNA-
repair activities of Ref-1 are encoded by nonoverlapping domains. Proc.
Natl. Acad. Sci. USA 91:23–27.
64. Yacoub, A., M. R. Kelley, and W. A. Deutsch. 1997. The DNA repair activity
of human redox/repair protein APE/Ref-1 is inactivated by phosphorylation.
Cancer Res. 57:5457–5459.
65. Yanagawa, H., Y. Ogawa, and M. Ueno. 1992. Redox ribonucleosides. Iso-
lation and characterization of 5-hydroxyuridine, 8-hydroxyguanosine, and
8-hydroxyadenosine from Torula yeast RNA. J. Biol. Chem. 267:13320–
13326.
66. Yoshida, A., Y. Urasaki, M. Waltham, A. C. Bergman, P. Pourquier, D. G.
Rothwell, M. Inuzuka, J. N. Weinstein, T. Ueda, E. Appella, I. D. Hickson,
and Y. Pommier. 2003. Human apurinic/apyrimidinic endonuclease (Ape1)
and its N-terminal truncated form (AN34) are involved in DNA fragmenta-
tion during apoptosis. J. Biol. Chem. 278:37768–37776.
67. Ziel, K. A., V. Grishko, C. C. Campbell, J. F. Breit, G. L. Wilson, and M. N.
Gillespie. 2005. Oxidants in signal transduction: impact on DNA integrity
and gene expression. FASEB J. 19:387–394.
1854 VASCOTTO ET AL. MOL. CELL. BIOL.
 o
n
 July 25, 2014 by Ruth Lilly M
edical Library
http://m
cb.asm
.org/
D
ow
nloaded from
 
